var title_f17_54_18272="Dutcher body";
var content_f17_54_18272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dutcher body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a patient with lymphoplasmacytic lymphoma and an IgM spike (Waldenstrom macroglobulinemia). There is an intranuclear inclusion in a lymphocyte (arrow) that represents precipitated IgM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18272=[""].join("\n");
var outline_f17_54_18272=null;
var title_f17_54_18273="Contents: Primary care dermatology";
var content_f17_54_18273=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care dermatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care dermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Benign and malignant melanocytic lesions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44056\">",
"           Acquired melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22009\">",
"           Pathologic characteristics of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/11/1206\">",
"           Pathologic evaluation of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24410\">",
"           Risk factors for the development of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35065\">",
"           Staging work-up and surveillance after treatment of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42488\">",
"           Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bites/Stings/Infestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39286\">",
"           Bedbugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/34/43556\">",
"           Chigger bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43016\">",
"           Jellyfish stings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25849\">",
"           Pediculosis capitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24339\">",
"           Pediculosis corporis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1511\">",
"           Pediculosis pubis and pediculosis ciliaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/2/28712\">",
"           Scabies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cutaneous lymphomas",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/47/25337\">",
"           Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4618\">",
"           Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35400\">",
"           Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15464\">",
"           Primary cutaneous follicle center lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26391\">",
"           Primary cutaneous large B cell lymphoma, leg type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26776\">",
"           Primary cutaneous marginal zone lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4713\">",
"           Staging and prognosis of mycosis fungoides and S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/35/36410\">",
"           Treatment of advanced stage (IIB to IV) mycosis fungoides and S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17017\">",
"           Treatment of early stage (IA to IIA) mycosis fungoides",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatologic procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31543\">",
"           Dermatologic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/45/40660\">",
"           Intralesional injection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12758\">",
"           Nail surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of pigmentation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/17/43287\">",
"           Benign pigmented skin lesions other than melanocytic nevi (moles)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of skin adnexal structures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24359\">",
"           HIV-associated eosinophilic folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/35/44599\">",
"           Hormonal therapy for women with acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/54/33639\">",
"           Light-based, adjunctive, and other therapies for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22184\">",
"           Oral isotretinoin therapy for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/7/6265\">",
"           Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1257\">",
"           Primary focal hyperhidrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36343\">",
"           Pseudofolliculitis barbae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39370\">",
"           Treatment of acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24266\">",
"           Treatment of hidradenitis suppurativa",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug eruptions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36986\">",
"           Cutaneous complications of conventional chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35834\">",
"           Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/17/41241\">",
"           Drug eruptions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33801\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General diagnosis and treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/28/37318\">",
"           Approach to the patient with a scalp eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29831\">",
"           Approach to the patient with macular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28423\">",
"           Approach to the patient with pustular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27752\">",
"           General principles of dermatologic therapy and topical corticosteroid use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/34/553\">",
"           Overview of benign lesions of the skin",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genital dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5336\">",
"           Dermatitis of the vulva",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36952\">",
"           Vulvar lichen planus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6874\">",
"           Vulvar lichen sclerosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hair and nails",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10856\">",
"           Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/46/1768\">",
"           Clinical manifestations and diagnosis of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4330\">",
"           Management of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12758\">",
"           Nail surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13846\">",
"           Nonscarring hair loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/61/37846\">",
"           Paronychia and ingrown toenails",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/9/37014\">",
"           Removal of unwanted hair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23336\">",
"           Treatment of androgenetic alopecia in men",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33365\">",
"           Botryomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26249\">",
"           Cutaneous warts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7082\">",
"           Dermatophyte (tinea) infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/43/11959\">",
"           Erythrasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29098\">",
"           Fever and rash in the immunocompetent patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23097\">",
"           Gianotti-Crosti syndrome (papular acrodermatitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6842\">",
"           Molluscum contagiosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/362\">",
"           Necrotizing soft tissue infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5258\">",
"           Onychomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31481\">",
"           Overview of Candida infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43142\">",
"           Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20152\">",
"           Skin lesions in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31687\">",
"           Soft tissue infections following water exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3320\">",
"           Tinea versicolor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/1/6170\">",
"           Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/18/21802\">",
"           Cutaneous manifestations of internal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29657\">",
"           Dermatoses of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13130\">",
"           Erythema nodosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18650\">",
"           Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31381\">",
"           Grover's disease (transient and persistent acantholytic dermatosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30614\">",
"           Hypersensitivity vasculitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1847\">",
"           Keloids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4774\">",
"           Management of intergluteal pilonidal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7285\">",
"           Metabolic and inherited diseases affecting the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31082\">",
"           Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/43/30393\">",
"           Neutrophilic dermatoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/11/25786\">",
"           Oral lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10090\">",
"           Pruritus: Etiology and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/58/6058\">",
"           Pruritus: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41767\">",
"           Treatment and prognosis of cutaneous mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39817\">",
"           Treatment and prognosis of systemic mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6874\">",
"           Vulvar lichen sclerosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Non-melanoma skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/35/6712\">",
"           Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7351\">",
"           Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/39/14970\">",
"           Epidemiology and clinical features of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/56/25482\">",
"           Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/5/44121\">",
"           Nevoid basal cell carcinoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/31/3577\">",
"           Staging and treatment of Merkel cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14293\">",
"           Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13690\">",
"           Treatment and prognosis of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31209\">",
"           Treatment and prognosis of cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30968\">",
"           Treatment of actinic keratosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Papulosquamous disorders and dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42631\">",
"           Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/62/27625\">",
"           Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9656\">",
"           Lichen planus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/4/41030\">",
"           Management of psoriasis in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44457\">",
"           Management of severe refractory atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3721\">",
"           Overview of dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/18999\">",
"           Pityriasis rosea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/44/20168\">",
"           Poison ivy (Toxicodendron) dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26551\">",
"           Role of allergy in atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/37/10842\">",
"           Treatment of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40042\">",
"           Treatment of psoriasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pediatric dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/13/22745\">",
"           Benign skin and scalp lesions in the newborn and young infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26104\">",
"           Contact dermatitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44665\">",
"           Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5495\">",
"           Evaluation and diagnosis of infantile hemangiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23097\">",
"           Gianotti-Crosti syndrome (papular acrodermatitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40985\">",
"           Localized scleroderma in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/60/25546\">",
"           Management of infantile hemangiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/33/37401\">",
"           Overview of diaper dermatitis in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6840\">",
"           Skin nodules in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4727\">",
"           Sturge-Weber syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24586\">",
"           The genodermatoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/21/30038\">",
"           Vascular lesions in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15864\">",
"           Vesiculobullous and pustular lesions in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Photodermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27142\">",
"           Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/63/18426\">",
"           Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/62/20455\">",
"           Polymorphous light eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/27/30136\">",
"           Sunburn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyrias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41687\">",
"           Hereditary coproporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30421\">",
"           Porphyria cutanea tarda and hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28458\">",
"           Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/51/825\">",
"           Variegate porphyria",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44087\">",
"           Classification of scleroderma disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43095\">",
"           Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31079\">",
"           Diagnosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/22/11626\">",
"           Initial treatment of dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39433\">",
"           Juvenile systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38566\">",
"           Malignancy in dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/33/36378\">",
"           Mucocutaneous manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29224\">",
"           Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/20/13642\">",
"           Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/11/37045\">",
"           Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/65\">",
"           Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13065\">",
"           Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30010\">",
"           Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24666\">",
"           Physical urticarias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-B859F3E640-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f17_54_18273=[""].join("\n");
var outline_f17_54_18273=null;
var title_f17_54_18274="Patient information: Marijuana use and addiction (The Basics)";
var content_f17_54_18274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/17/37137\">",
"         Patient information: Alcohol poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/21/44371\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/23/4468\">",
"         Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Marijuana use and addiction (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/marijuana-use-and-addiction-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5393399\">",
"      <span class=\"h1\">",
"       What is marijuana?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Marijuana is a drug that comes from the leaves and flowers of a plant. (The plant is also called marijuana.) In the US, marijuana is usually sold in the form of leaves and buds. In Europe, a different form of marijuana is more common. It is called &ldquo;hashish&rdquo; and is made from a sticky substance that comes from the plant. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393406\">",
"      <span class=\"h1\">",
"       What does marijuana do to the brain and body?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Marijuana can make you feel happy and relaxed. It can also make you feel less anxious, tense, and depressed. But it does bad things, too. It makes it hard to focus or remember things, or to think clearly. Plus, it slows your reaction time and impairs your judgement.",
"     </p>",
"     <p>",
"      Marijuana can also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make your heart race",
"       </li>",
"       <li>",
"        Raise your blood pressure",
"       </li>",
"       <li>",
"        Make you breathe faster",
"       </li>",
"       <li>",
"        Make your eyes red",
"       </li>",
"       <li>",
"        Make your mouth dry",
"       </li>",
"       <li>",
"        Make you hungry",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393413\">",
"      <span class=\"h1\">",
"       Who uses marijuana?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Marijuana use is common in the US. Almost half of all Americans have tried marijuana at least once. About 9 percent of Americans have used it in the last year. Younger people are more likely than older people to use it, and men are more likely than women to use it. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393420\">",
"      <span class=\"h1\">",
"       Does marijuana have any medical benefits?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Marijuana might help ease pain and other symptoms caused by cancer or cancer treatment. It might also help with the symptoms of multiple sclerosis. Some medicines are made from the same active ingredients that are in marijuana. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393427\">",
"      <span class=\"h1\">",
"       How can you tell if someone has a problem with marijuana use?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have a problem with marijuana use have 1 or more of these issues:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        They often don&rsquo;t do things that are expected of them, such as go to work or school, remember family events, and clean their home.",
"       </li>",
"       <li>",
"        They have problems in their relationships with other people.",
"       </li>",
"       <li>",
"        They sometimes have legal problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393434\">",
"      <span class=\"h1\">",
"       How can you tell if someone is addicted to marijuana?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who are addicted to marijuana can have the same issues listed above for problem users. They also have 3 or more of these problems:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        They need to use more and more to get the same effects they used to get with less use. Or they get less effect from using the amount that used to get them high. This is called &ldquo;tolerance.&rdquo;",
"       </li>",
"       <li>",
"        They end up using more marijuana than they planned to, or they use it for longer than they planned to. &nbsp;",
"       </li>",
"       <li>",
"        They wish they could cut down on marijuana, but they can&rsquo;t.",
"       </li>",
"       <li>",
"        They spend a lot of time trying to get marijuana, getting high, or recovering from being high. &nbsp;",
"       </li>",
"       <li>",
"        They keep using marijuana even if it causes them health problems or other problems in their life. &nbsp;",
"       </li>",
"       <li>",
"        They have &ldquo;withdrawal symptoms&rdquo; if they stop using marijuana after using it for a long time. Withdrawal symptoms can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Yawning, feeling tired, or sleeping too much",
"       </li>",
"       <li>",
"        Slowed thoughts and movements",
"       </li>",
"       <li>",
"        Feeling irritable, tense, or anxious",
"       </li>",
"       <li>",
"        Feeling sad or depressed",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393441\">",
"      <span class=\"h1\">",
"       How is marijuana addiction treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, treatment involves different types of &ldquo;talk therapy.&rdquo; Talk therapy is when you work with a psychiatrist, psychologist, social worker, or other mental health expert to stop using the drug.",
"     </p>",
"     <p>",
"      For talk therapy, people see a counselor, usually once a week for about an hour. There are different types of talk therapy, and a person might have more than 1 type. The types of therapy that help with marijuana addiction include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Cognitive behavioral therapy, or &ldquo;CBT&rdquo;",
"        </strong>",
"        &mdash; CBT can help people stop using drugs that are harmful to them. During CBT, you work with a therapist to better understand:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        What led to your marijuana use in the past and most recently",
"       </li>",
"       <li>",
"        How your marijuana use affects your life",
"       </li>",
"       <li>",
"        Why it is hard to stop using marijuana &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Motivational interviewing",
"        </strong>",
"        &mdash; During motivational interviewing, the counselor does not tell you what to do. Instead, the counselor tries to help you figure out for yourself what is best. This type of counseling is especially helpful for people who are not sure they have a problem. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Voucher-based incentives",
"        </strong>",
"        &mdash; In voucher-based treatment, you get rewarded for coming to sessions and not using the drug.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Family therapy",
"        </strong>",
"        &mdash; Family therapy focuses on the whole family, not just the person with addiction. It is especially helpful for children or teens with addiction. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with addiction can also get help on their own, from groups such as Marijuana Anonymous (",
"      <a class=\"external\" href=\"file://www.marijuana-anonymous.org/\">",
"       www.marijuana-anonymous.org",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5393553\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37137?source=see_link\">",
"       Patient information: Alcohol poisoning (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=see_link\">",
"       Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/54/18274?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16444 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18274=[""].join("\n");
var outline_f17_54_18274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393399\">",
"      What is marijuana?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393406\">",
"      What does marijuana do to the brain and body?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393413\">",
"      Who uses marijuana?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393420\">",
"      Does marijuana have any medical benefits?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393427\">",
"      How can you tell if someone has a problem with marijuana use?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393434\">",
"      How can you tell if someone is addicted to marijuana?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393441\">",
"      How is marijuana addiction treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5393553\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37137?source=related_link\">",
"      Patient information: Alcohol poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_54_18275="Double cervix in situ";
var content_f17_54_18275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Double cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A and B) Two cervices are shown in situ. The rugated vaginal walls can be seen laterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the Surgical Planning Laboratory at Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18275=[""].join("\n");
var outline_f17_54_18275=null;
var title_f17_54_18276="Ofatumumab: Patient drug information";
var content_f17_54_18276=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ofatumumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     see \"Ofatumumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9524862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arzerra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16053099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Arzerra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ofatumumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done. A hepatitis B infection may get worse during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen, diphenhydramine, and a corticosteroid may be given before this drug to lower fever and chills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12269 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18276=[""].join("\n");
var outline_f17_54_18276=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524862\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16053099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023717\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023716\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023721\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023722\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023724\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023719\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023726\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=related_link\">",
"      Ofatumumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_54_18277="Rotigotine: Patient drug information";
var content_f17_54_18277=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rotigotine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/45/5846?source=see_link\">",
"     see \"Rotigotine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14699479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neupro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14218986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14218985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731885",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rotigotine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14218990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696692",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of heat sources (such as sunlamps, tanning beds, heating pads, electric blankets, heat lamps, saunas, hot tubs, heated waterbeds). Avoid long, hot baths or sunbathing. Your temperature may rise and cause too much drug to pass into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14219080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14218991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698652",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Falling asleep during activities such as eating or talking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Strong urges that are hard to control (such as gambling or sex).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any skin change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14218988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use patches that are cut or do not look right.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3744544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the belly, hip, lower back, shoulder, upper leg, or upper arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694470",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3744542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shave hair at a site 3 days before putting a patch on it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3744543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Press patch firmly in place for 30 seconds when putting it on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the patch site with each new patch. Do not put on the same site for 14 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3744545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful to not knock loose the patch while bathing or showering.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch falls off, put a new one on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3688608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch loosens, put tape ONLY on the edges of the patch to hold it in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3744546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When patch is taken off, wash site with soap and water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14218989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14219088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After you take off a skin patch, be sure to fold the sticky sides of the patch to each other.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14218992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83514 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18277=[""].join("\n");
var outline_f17_54_18277=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14699479\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218986\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218985\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218990\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14219080\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218991\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218988\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218989\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14219088\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14218992\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/45/5846?source=related_link\">",
"      Rotigotine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_54_18278="EEG lateral epileptic activity";
var content_f17_54_18278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Periodic lateralized epileptic discharges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recordings from the right lateral temporal and parietal electrodes demonstrates slow lateralized slow activity and epileptic discharges. The presence of periodic lateralized epileptic discharges (PLEDs) is suggestive of encephalitis, often due to infection by herpes simplex virus type 1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18278=[""].join("\n");
var outline_f17_54_18278=null;
var title_f17_54_18279="M mode hypertrophic CM";
var content_f17_54_18279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of hypertrophic cardimyopathy with dynamic obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-Mode echocardiogram taken at rest (panel A) shows diastolic mitral valve (MV) septal contact, a low intensity murmur (SEM) and a modest degree of systolic anterior motion (SAM) of the mitral valve. In panel B, taken at peak amyl nitrite effect, the MV during is in contact with the septum during much of diastole and during systole as a result of SAM; it gives the impression that the mitral apparatus is \"crowded\". The presence of SAM and crowding, the carotid pulse (cp) configuration and the now intense SEM are features that signify the dynamic nature of the obstruction and that the provoked obstruction is severe. In panel C, the obstruction has abated a few minutes after the peak amyl nitrate effect has subsided; however obstruction remains detectable by cp configuration and by SEM intensity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18279=[""].join("\n");
var outline_f17_54_18279=null;
var title_f17_54_18280="Neurologic complications of bacterial meningitis in adults";
var content_f17_54_18280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of bacterial meningitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18280/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18280/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18280/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18280/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/54/18280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis continues to result in substantial morbidity and mortality despite the availability of effective antimicrobial therapy. The risk of dying or of developing complications is related to the age and general health of the patient, to the causative pathogen, to the severity and duration of illness at the time of presentation, and, occasionally, to delays in the initiation of antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications due to bacterial meningitis can be divided into systemic and neurologic. Systemic complications such as septic shock, disseminated intravascular coagulation, acute respiratory distress syndrome, and septic or reactive arthritis, are usually the consequence of the bacteremia that frequently accompanies meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic complications of bacterial meningitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired mental status",
"     </li>",
"     <li>",
"      Increased intracranial pressure and cerebral edema",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal neurologic deficits (eg, cranial nerve palsy, hemiparesis)",
"     </li>",
"     <li>",
"      Cerebrovascular abnormalities",
"     </li>",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Intellectual impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications may be sudden or gradual in onset and can appear at any time after the onset of symptoms, including after the completion of therapy. Although many neurologic complications are severe, others, such as hearing loss, may be subtle or inapparent during the early phases of infection.",
"   </p>",
"   <p>",
"    The neurologic complications of meningitis in adults will be reviewed here. The possible protective role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy to prevent neurologic complications in selected patients and more general issues, such as the clinical manifestations, diagnosis, treatment, and prognosis of bacterial meningitis in adults, as well as neurologic complications in neonates and children with bacterial meningitis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications are not uncommon in adults with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In a review of 493 episodes of bacterial meningitis in adults, 28 percent of community-acquired episodes resulted in one or more neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. No distinction was made in this study between transient and long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. This is an important clinical issue, since many complications are transient. The usually short duration of neurologic complications was illustrated in a report of 269 adults with community-acquired bacterial meningitis: a neurologic deficit developed in 21 percent during the course of the illness, but only 9 percent had a neurologic deficit at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/3\">",
"     3",
"    </a>",
"    ]. The major persistent abnormal neurologic findings were hearing loss, a major motor deficit, impaired cognition or speech, and cranial nerve palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prediction of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline features can be used to estimate the individual risk for an adverse neurologic outcome in adults with bacterial meningitis. A prognostic model was derived from a cohort of 176 adults and then validated in another cohort of 93 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/3\">",
"     3",
"    </a>",
"    ]. The in-hospital mortality was 27 percent, and a neurologic deficit at discharge was present in 9 percent. Three baseline clinical features &mdash; hypotension, altered mental status, and seizures &mdash; were independently associated with an adverse outcome (defined as in-hospital death or neurologic deficit at discharge) and stratified the patients into three risk groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (no clinical risk factors) &mdash; 9 percent adverse outcome",
"     </li>",
"     <li>",
"      Intermediate risk (one clinical risk factor) &mdash; 33 percent adverse outcome",
"     </li>",
"     <li>",
"      High risk (two or three risk factors) &mdash; 56 percent adverse outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delay in initial antibiotics in the emergency department (median delay of four hours) was associated with a worsening of these markers in about 15 percent of adults. Those patients whose delay in antibiotic therapy allowed their disease to advance from having zero or one to having two or three poor prognostic indicators had a significant increase in adverse outcomes. The last finding supports the general recommendation to avoid delays in antimicrobial therapy in patients with suspected bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Avoidance of delay'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the above general risk factors, the rate of complications is greatest in patients with pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. This may result in part from the persistence of potent biologic activity in the debris of killed bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/7\">",
"     7",
"    </a>",
"    ]. The debris may stimulate the host inflammatory response, which in turn contributes to tissue damage. This phenomenon may also contribute to the reduction in neurologic complications seen in some patients with pneumococcal meningitis who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEUROLOGIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, neurologic complications can develop at any time during the course of bacterial meningitis. Impaired mental status is seen in most patients at presentation, and seizures are more often seen during the acute episode. Although also occurring early, sensorineural hearing loss is typically not appreciated until the patient has recovered from the acute illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Presenting manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients who develop neurologic complications but survive the acute episode improve with appropriate therapy of the meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a study of 301 adults in whom mental status was assessed by the Glasgow outcome scale at eight weeks in the 269 survivors, 90 percent had mild or no disability, 7 percent had moderate disability, and 3 percent had severe disability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with substantial impairment in consciousness on admission were more likely to have unfavorable long-term outcomes. Similar findings were noted in the review of 269 patients in which 9 percent of survivors had a neurologic deficit at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher rate of moderate to severe neurologic disability at discharge (34 percent) was noted in a later study of 696 adults from the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/5\">",
"     5",
"    </a>",
"    ]. The rate was much higher with pneumococcal compared with meningococcal meningitis (50 versus 12 percent). This finding is consistent with the generally worse outcomes and increased mortality seen with pneumococcal compared with other causes of bacterial meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H31#H31\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concern about both the mortality and morbidity of bacterial meningitis has led to the administration of adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in selected patients. The data supporting this approach and the indications for dexamethasone therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Altered mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered mental status is a common presenting feature in children and adults with bacterial meningitis. The major cause of severely diminished consciousness and coma is increased intracranial pressure.",
"   </p>",
"   <p>",
"    In large studies of bacterial meningitis in adults, the incidence of altered mental status ranged from 78 to 83 percent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In the review of 279 patients with community-acquired meningitis, for example, the mental status was altered in 78 percent at presentation. Most patients were confused or lethargic, but 22 percent were responsive only to pain and 6 percent were unresponsive to all stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. In other series, coma [defined as Glasgow coma score &lt;8; (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    )] was noted in 14 to 16 percent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with bacterial meningitis develop increased intracranial pressure (ICP), which can produce a number of clinical signs or problems. Mild to moderate increases in intracranial pressure typically cause headache, confusion, irritability, nausea, and vomiting. More severe increases can produce one or more of the following.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mental status that can include coma",
"     </li>",
"     <li>",
"      Bradycardia with hypertension (the Cushing reflex)",
"     </li>",
"     <li>",
"      Papilledema, sometimes with loss of vision, which has been described in 4 to 9 percent of adults [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cranial nerve palsy, particularly involving the abducens (VI) nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Herniation of the cerebellar tonsils leading to death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Raised intracranial pressure in patients with meningitis is primarily due to cerebral edema, which can be caused by vasogenic, cytotoxic, or interstitial mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/8\">",
"     8",
"    </a>",
"    ]. The net effect of these processes is the same: an increase in the intercellular fluid volume of the brain, leading to a rise in intracranial pressure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasogenic cerebral edema usually results from increased permeability of the blood-brain barrier, especially in the choroid plexus endothelium and the endothelium of the cerebral microvasculature.",
"     </li>",
"     <li>",
"      Cytotoxic factors released from neutrophils and bacteria can directly produce cerebral edema.",
"     </li>",
"     <li>",
"      The inflammation produced by the infection can impede the normal absorption of CSF from the subarachnoid space via the arachnoid villi.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cerebral perfusion pressure, normally maintained by an autoregulatory mechanism, becomes dependent upon peripheral blood pressure during meningitis because autoregulation is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Cerebral edema itself can increase the intracranial pressure and secondarily reduce cerebral blood flow.",
"   </p>",
"   <p>",
"    The possible presence of cerebral edema should be considered in all critically ill patients with meningitis. Treatment of intracranial hypertension can be initiated if the diagnosis is confirmed by neuroimaging studies or earlier if strongly suspected on clinical grounds (eg, papilledema, fixed dilated pupil).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    both decreases intracranial pressure and increases vascular perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur in 15 to 30 percent of adults with acute bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2-5,11\">",
"     2-5,11",
"    </a>",
"    ]. The pathogenesis of seizures in meningitis is not well understood. Although fever may be a cofactor in very young children, bacterial toxins or secondary neurochemical changes are presumably the cause of most seizures. In one study, for example, the occurrence of seizures correlated with colony counts of greater than 10(7) colony-forming units (CFU) in the CSF sample prior to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures can be present at the time of admission or develop during hospitalization. In a prospective study of 696 episodes of community-acquired bacterial meningitis in adults, seizures occurred in 5 percent before admission and 15 percent after admission; the median time between admission and the first seizure was one day [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. Early-onset seizures are more common in patients with a history of alcoholism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. Seizures can be generalized or focal.",
"   </p>",
"   <p>",
"    The incidence of seizures was significantly increased in patients with pneumococcal meningitis (24 versus 5 percent with meningococcal meningitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/5,11\">",
"     5,11",
"    </a>",
"    ], a finding noted in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. Other risk factors for seizures in one of these series were a predisposing condition, tachycardia, low Glasgow Coma Scale score, focal neurologic deficits, a low CSF WBC count (&lt;1000",
"    <span class=\"nowrap\">",
"     cells/mm3),",
"    </span>",
"    and a higher CSF protein level [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/11\">",
"     11",
"    </a>",
"    ]. In a randomized, placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy, seizures were less likely in the treated patient group (5 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures during an episode of acute meningitis are often a poor prognostic sign in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. In one series of 696 patients with community-acquired bacterial meningitis, seizures were associated with a higher risk of neurologic deficits at hospital discharge (24 versus 6 percent) and death (41 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/11\">",
"     11",
"    </a>",
"    ]. All five patients with status epilepticus in this case series died.",
"   </p>",
"   <p>",
"    Adults who have seizures during an episode of meningitis have a small but significant risk of seizures after recovery. In a follow-up study of 199 adult survivors of bacterial meningitis, patients with seizures during the acute illness were more likely to develop recurrent seizures within five years than those without seizures in the acute phase (8 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/13\">",
"     13",
"    </a>",
"    ]. A similar frequency of late recurrence (3 percent) was noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Focal neurologic deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal neurologic deficits are common complications of meningitis, with an incidence ranging from 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. The deficits include cranial nerve palsy, monoparesis, hemiparesis, gaze preference, visual field defects, aphasia, and ataxia and most are present on admission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In the review of 279 episodes of community-acquired bacterial meningitis, for example, 7 percent had focal seizures and 28 percent developed a focal neurologic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. Hemiparesis, aphasia, and gaze preference were the most common focal abnormalities. The onset of focal findings was within the first 24 hours in almost 90 percent of patients.",
"   </p>",
"   <p>",
"    As with other neurologic complications, the rate of focal deficits is significantly higher in adults with pneumococcal meningitis compared to other pathogens. In one series, the incidence of focal deficits was 23 percent in pneumococcal meningitis compared with 9 and 3 percent in meningococcal meningitis and patients with negative cultures, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/4\">",
"     4",
"    </a>",
"    ]. In another series, focal neurologic deficits were present at discharge in 65 percent of those with pneumococcal versus 33 percent with meningococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most focal deficits resolve with successful treatment of the meningitis, but long-term disability can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cranial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial nerve palsies have been described in 5 to 11 percent of patients and can occur alone or with other focal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In the review of 279 episodes of community-acquired bacterial meningitis in adults, 12 patients (4 percent) had a cranial nerve palsy as the only focal neurologic finding; the neuropathy was present in nine on admission and developed within 24 hours in the other three [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cranial nerve palsies can result from compression due to brain swelling or from perineuritis due to the adjacent meningeal inflammatory reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. The abducens (VI) nerve is the cranial nerve most commonly affected in meningitis, probably because its long intracranial segment adjacent to the brainstem is highly vulnerable to the elevated intracranial pressure and inflammatory reaction that can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. Cranial nerves III, IV and VII also may become impaired in patients with meningitis. Deficits in all of these nerves are usually transient.",
"   </p>",
"   <p>",
"    Bacterial meningitis can induce arachnoiditis around the optic nerve, which can lead to transient or permanent visual loss. Optic atrophy that results in irreversible total blindness is a rare complication of severe meningitis.",
"   </p>",
"   <p>",
"    Another rare focal finding in patients with bacterial meningitis is cranial neuropathy due to reactivation of herpes zoster virus (Ramsay Hunt syndrome, also called herpes zoster oticus) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Ramsay Hunt syndrome (Herpes zoster oticus)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hemiparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other focal neurologic signs that may occur in bacterial meningitis include hemiparesis or quadriparesis. The reported incidence of hemiparesis has ranged from 4 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In the series of 279 patients with community-acquired meningitis, for example, hemiparesis developed in 37 (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. An intracranial abnormality was eventually demonstrated in 13 of the 37 patients, including cortical vein or sagittal vein thrombosis, cerebral artery spasm, subdural hematoma, hydrocephalus, a cerebral infarct or abscess, and cerebral edema. The hemiparesis resolved by discharge in 18 of the 25 survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerebrovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis, vasculitis, acute cerebral hemorrhage, and aneurysm formation of large, medium or small cerebral vessels are potential complications of bacterial meningitis. These diverse processes can manifest similarly as a focal abnormality, such as hemiparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,16\">",
"     2,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 86 adults with bacterial meningitis, cerebral angiography was performed in 27 (31 percent) because one or more of the following findings were present: focal neurologic deficits, abnormalities on computed tomographic (CT) scanning, or persistent coma after three days of antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/16\">",
"     16",
"    </a>",
"    ]. Abnormal angiograms were found in 13 of these 27 patients; the abnormal findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vessel wall irregularities and focal dilatations",
"     </li>",
"     <li>",
"      Arterial occlusions",
"     </li>",
"     <li>",
"      Focal arterial bleeding",
"     </li>",
"     <li>",
"      Thrombosis of the superior sagittal and cortical veins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another report, a cranial CT scan was performed in 87 of 122 adults with bacterial meningitis seen after 1975 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"     2",
"    </a>",
"    ]. A cerebral infarct was noted in four, lesions consistent with septic emboli in two and cavernous sinus thrombosis in one. Four patients without a lesion on initial scan had signs of an infarct on a later CT scan that was performed because of persistent hemiparesis in three and triplegia in one.",
"   </p>",
"   <p>",
"    One report describes a series of six patients who developed cerebral thrombosis affecting the brainstem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thalamus as a subacute complication of pneumococcal meningitis 7 to 19 days after initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/17\">",
"     17",
"    </a>",
"    ]. All patients had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    initially, and five were treated again with high-dose steroids upon deterioration. Two patients survived with moderate to severe disability. Postmortem studies on two patients revealed thrombosis of penetrating arteries without evidence of vasculitis.",
"   </p>",
"   <p>",
"    Among 68 patients admitted to a neurologic intensive care unit with bacterial meningitis, a reduced level of consciousness at the time of admission and a low white blood cell count in the cerebrospinal fluid were found to be predictive factors for cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other rare cerebrovascular complications have been described in isolated reports. These include hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/2,19\">",
"     2,19",
"    </a>",
"    ] and thrombotic infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subarachnoid hemorrhage into the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/20\">",
"     20",
"    </a>",
"    ]. Hemorrhagic strokes presumably occur when the inflammatory reaction in the subarachnoid space produces either vessel erosion or aneurysm formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sensorineural hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensorineural hearing loss after bacterial meningitis may be transient or permanent. Transient hearing loss is usually secondary to a conductive disturbance, whereas permanent hearing loss can result from damage to the eighth cranial nerve, cochlea, or labyrinth induced by direct bacterial invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the inflammatory response elicited by the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in adults have shown hearing loss in 12 to 14 percent, with a higher rate in pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/4,5,25\">",
"     4,5,25",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 119 survivors in the placebo group in a randomized controlled trial evaluating the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , hearing loss was present at eight weeks after admission in 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/4\">",
"       4",
"      </a>",
"      ]. As with most other neurologic complications, the incidence of hearing loss was greater in patients with S. pneumoniae infection than in those with Neisseria meningitidis or negative cultures (21 versus 11 and 4 percent, respectively).",
"     </li>",
"     <li>",
"      Similar results were noted in the series of 696 adults with bacterial meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/5\">",
"       5",
"      </a>",
"      ]. Among the 550 survivors to discharge, hearing loss was present in 14 percent, with a higher rate in pneumococcal compared to meningococcal meningitis (22 versus 8 percent).",
"     </li>",
"     <li>",
"      In a retrospective study based upon a national registry, among 240 patients with pneumococcal meningitis who underwent audiometry, 129 (54 percent) had a hearing deficit [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/26\">",
"       26",
"      </a>",
"      ]. Fifty of the 129 (39 percent) patients with a hearing deficit were not suspected of having a hearing deficit at hospital discharge. Of the 240 patients, 16 (7 percent) had profound unilateral hearing loss and another 16 (7 percent) had profound bilateral hearing loss. Using multivariate analysis, risk factors for hearing loss were advanced age, female gender, and certain serotypes; serotypes 6B and 14 were associated with a lower risk of hearing loss than serotype 12F.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A mouse model of pneumococcal meningitis suggested a role for the toll-like receptor-associated adapter molecule MyD88 in the development of cochlear inflammation and hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intellectual impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychological impairment is common in survivors of bacterial meningitis. A meta-analysis of three trials including 155 adult survivors of bacterial meningitis found that cognitive impairment occurred in 32 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/28\">",
"     28",
"    </a>",
"    ]. The meta-analysis found no difference in cognitive impairment between survivors of pneumococcal and meningococcal meningitis, although two of the studies included found worse cognitive outcomes in patients with pneumococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    does not appear to alter the incidence of cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Unusual complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other neurologic complications rarely occur in adults with bacterial meningitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extraaxial fluid collections that are infected (subdural empyemas) or sterile (subdural effusions or hygromas). Drainage is mandatory if subdural empyema develops. Detecting subdural empyemas and distinguishing them from sterile fluid collections requires correlation between clinical and imaging findings.",
"     </li>",
"     <li>",
"      Spinal cord complications such as transverse myelitis or infarction, presumably as a direct result of local vascular changes with secondary cord ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain abscesses and focal cerebritis may be causes of or complications of meningitis. When they are complications of meningitis, they occur with higher frequency in patients infected with certain uncommon causes of meningitis such as Enterobacter or Citrobacter spp [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/21\">",
"       21",
"      </a>",
"      ], and tend to occur in the frontal or temporal lobes at the grey-white matter junction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe permanent hydrocephalus.",
"     </li>",
"     <li>",
"      Aneurysm formation of focal intracranial vessels, presumably secondary to inflammatory changes in the blood vessel wall [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ventriculitis, which may manifest as thickening and ependymal enhancement, generalized or segmental ventricular dilatation, and debris in the dependent portions of the ventricles by CT or magnetic resonance imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18280/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       \"Patient information: Bacterial meningitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9802243\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial meningitis continues to result in substantial morbidity and mortality despite the availability of effective antimicrobial therapy. The risk of dying or of developing complications is related to the age and general health of the patient, the causative pathogen, the severity and duration of illness at the time of presentation, and, occasionally, to delays in the initiation of antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications due to bacterial meningitis can be divided into systemic and neurologic. Systemic complications such as septic shock, disseminated intravascular coagulation, acute respiratory distress syndrome, and septic or reactive arthritis, are usually the consequence of the bacteremia that frequently accompanies meningitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neurologic complications of bacterial meningitis include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Impaired mental status",
"     </li>",
"     <li>",
"      Increased intracranial pressure and cerebral edema",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal neurologic deficits (eg, cranial nerve palsy, hemiparesis)",
"     </li>",
"     <li>",
"      Cerebrovascular abnormalities",
"     </li>",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Intellectual impairment (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic complications are not uncommon in adults with bacterial meningitis, but many complications are transient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic complications can develop at any time during the course of bacterial meningitis. Impaired mental status is seen in most patients at presentation, and seizures are more often seen during the acute episode. Although also occurring early, sensorineural hearing loss is typically not appreciated until the patient has recovered from the acute illness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neurologic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concern about both the mortality and morbidity of bacterial meningitis has led to the administration of adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in selected patients. The data supporting this approach and the indications for dexamethasone therapy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"       \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/1\">",
"      Pfister HW, Feiden W, Einh&auml;upl KM. Spectrum of complications during bacterial meningitis in adults. Results of a prospective clinical study. Arch Neurol 1993; 50:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/2\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/3\">",
"      Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/4\">",
"      de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/5\">",
"      van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/6\">",
"      Talan DA, Zibulewsky J. Relationship of clinical presentation to time to antibiotics for the emergency department management of suspected bacterial meningitis. Ann Emerg Med 1993; 22:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/7\">",
"      Tuomanen E, Hengstler B, Rich R, et al. Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis. J Infect Dis 1987; 155:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/8\">",
"      Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993; 6:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/9\">",
"      Tureen JH, Dworkin RJ, Kennedy SL, et al. Loss of cerebrovascular autoregulation in experimental meningitis in rabbits. J Clin Invest 1990; 85:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/10\">",
"      Goitein KJ, Tamir I. Cerebral perfusion pressure in central nervous system infections of infancy and childhood. J Pediatr 1983; 103:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/11\">",
"      Zoons E, Weisfelt M, de Gans J, et al. Seizures in adults with bacterial meningitis. Neurology 2008; 70:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/12\">",
"      Feldman WE. Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis. N Engl J Med 1977; 296:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/13\">",
"      Annegers JF, Hauser WA, Beghi E, et al. The risk of unprovoked seizures after encephalitis and meningitis. Neurology 1988; 38:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/14\">",
"      DODGE PR, SWARTZ MN. BACTERIAL MENINGITIS--A REVIEW OF SELECTED ASPECTS. II. SPECIAL NEUROLOGIC PROBLEMS, POSTMENINGITIC COMPLACATIONS AND CLINICOPATHOLOGICAL CORRELATIONS. N Engl J Med 1965; 272:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/15\">",
"      Steven NM, Nathwani D. Facial palsy, meningococcal meningitis, and reactivation of herpes simplex virus. Clin Infect Dis 1993; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/16\">",
"      Pfister HW, Borasio GD, Dirnagl U, et al. Cerebrovascular complications of bacterial meningitis in adults. Neurology 1992; 42:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/17\">",
"      Schut ES, Brouwer MC, de Gans J, et al. Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis. Neurology 2009; 73:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/18\">",
"      Katchanov J, Heuschmann PU, Endres M, Weber JR. Cerebral infarction in bacterial meningitis: predictive factors and outcome. J Neurol 2010; 257:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/19\">",
"      Gironell A, Domingo P, Mancebo J, et al. Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. Clin Infect Dis 1995; 21:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/20\">",
"      Perry JR, Bilbao JM, Gray T. Fatal basilar vasculopathy complicating bacterial meningitis. Stroke 1992; 23:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/21\">",
"      Kaplan SL, Woods CR. Neurologic complications of bacterial meningitis in children. Curr Clin Top Infect Dis 1992; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/22\">",
"      Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984; 311:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/23\">",
"      Bhatt SM, Lauretano A, Cabellos C, et al. Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. J Infect Dis 1993; 167:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/24\">",
"      Merchant SN, Gopen Q. A human temporal bone study of acute bacterial meningogenic labyrinthitis. Am J Otol 1996; 17:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/25\">",
"      Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003; 126:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/26\">",
"      Wors&oslash;e L, Cay&eacute;-Thomasen P, Brandt CT, et al. Factors associated with the occurrence of hearing loss after pneumococcal meningitis. Clin Infect Dis 2010; 51:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/27\">",
"      Klein M, Schmidt C, Kastenbauer S, et al. MyD88-dependent immune response contributes to hearing loss in experimental pneumococcal meningitis. J Infect Dis 2007; 195:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/28\">",
"      Hoogman M, van de Beek D, Weisfelt M, et al. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 2007; 78:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/29\">",
"      van de Beek D, Schmand B, de Gans J, et al. Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis 2002; 186:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/30\">",
"      Weisfelt M, Hoogman M, van de Beek D, et al. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol 2006; 60:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/31\">",
"      Seay AR. Spinal cord dysfunction complicating bacterial meningitis. Arch Neurol 1984; 41:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18280/abstract/32\">",
"      Hughes DC, Raghavan A, Mordekar SR, et al. Role of imaging in the diagnosis of acute bacterial meningitis and its complications. Postgrad Med J 2010; 86:478.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1291 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18280=[""].join("\n");
var outline_f17_54_18280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9802243\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prediction of risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEUROLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Altered mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increased intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Focal neurologic deficits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cranial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hemiparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerebrovascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sensorineural hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intellectual impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Unusual complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9802243\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_54_18281="Aspirin exacerbated respiratory disease: NSAID challenge and desensitization";
var content_f17_54_18281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aspirin exacerbated respiratory disease: NSAID challenge and desensitization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18281/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18281/contributors\">",
"     Ronald A Simon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18281/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18281/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/54/18281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14130927\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) present with one or more of the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Chronic rhinosinusitis (CRS) with nasal polyposis",
"     </li>",
"     <li>",
"      Reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (acetylsalicylic acid, ASA) and other COX-1 inhibiting nonsteroidal antiinflammatory drugs (NSAIDs), in which symptoms begin 30 minutes to 3 hours after ingestion and characteristically involve the upper and lower airways (eg, nasal congestion and bronchospasm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131015\">",
"    <span class=\"h2\">",
"     Pseudoallergic NSAID reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AERD can develop intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other structurally distinct NSAIDS, which are categorized as",
"    <strong>",
"     type 1",
"    </strong>",
"    pseudoallergy. These reactions are classified as pseudoallergic because they are not immunologically mediated, although they can be as severe as IgE-mediated anaphylaxis. Mechanistically, symptoms result from an abnormal biochemical response to the pharmacologic actions of NSAIDs.",
"   </p>",
"   <p>",
"    NSAID challenge protocols involve cautiously administering gradually increasing doses of an NSAID, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , in an appropriately monitored medical setting. These procedures are used to diagnose NSAID pseudoallergy and also to desensitize AERD patients to NSAIDs, when indicated. The safety and technical aspects of these protocols are discussed here. The clinical manifestations and management of AERD, and a general discussion of allergic and pseudoallergic reactions to NSAIDs are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003220\">",
"    <span class=\"h1\">",
"     OVERVIEW OF NSAID CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID challenges are structured protocols in which the patient is given incrementally increasing doses of an NSAID under medical supervision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131689\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID challenges are usually performed by allergy specialists with expertise in drug allergy and the training, medications, equipment, and support staff needed to manage any resultant symptoms, whenever possible. In addition, there are several types of NSAID reactions, and determining which type is likely present can require some expertise. In some centers (especially in Europe), pulmonary and otolaryngology specialists perform NSAID challenges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131210\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Challenges in patients with suspected type I pseudoallergy are provocative challenges; they are likely to induce symptoms, albeit in a controlled and limited manner. These protocols differ from most other types of drug challenges (particularly those for IgE-mediated allergic reactions such as anaphylaxis), which are performed only on patients who are",
"    <strong>",
"     not",
"    </strong>",
"    believed to be allergic, in order to confirm",
"    <strong>",
"     lack",
"    </strong>",
"    of allergy.",
"   </p>",
"   <p>",
"    Because NSAID challenges in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) are likely to provoke symptoms, the following precautions are necessary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Challenges should be performed in a medically-monitored setting. In most cases, these protocols may be safely performed in specially-equipped outpatient allergy clinics, although the decision about where to perform challenges requires clinical judgment and each case must be considered individually.",
"     </li>",
"     <li>",
"      The patient&rsquo;s asthma should be well-controlled because NSAID challenges may induce wheezing and bronchospasm.",
"     </li>",
"     <li>",
"      Published challenge protocols call for obtaining intravenous access prior to challenge as a precaution in case IV medications or fluids are required. However, while this is the common practice, neither the author nor editors of this topic have needed to administer IV fluids or medications to a patient with AERD undergoing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      challenge.",
"     </li>",
"     <li>",
"      Informed consent should be obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131255\">",
"    <span class=\"h2\">",
"     Indications for challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID challenge protocols are performed either to diagnose NSAID pseudoallergy or to desensitize the patient to NSAIDs in order to administer NSAIDs on a regular basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diagnosis of NSAID pseudoallergy",
"      </strong>",
"      : There are no in vitro or skin testing methods available to diagnose NSAID pseudoallergy, and a provocative challenge procedure is the only means of obtaining a definitive diagnosis. In patients with AERD, an NSAID challenge that results in characteristic nasal, ocular,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory symptoms is diagnostic of type 1 pseudoallergy. However, outside of research settings, challenges are uncommonly performed solely for the purpose of diagnosis, as they are not without risk to the patient.",
"     </li>",
"     <li>",
"      <strong>",
"       Desensitization to NSAIDs",
"      </strong>",
"      : Desensitization is performed by extending the challenge procedure beyond the initial induction of symptoms. Desensitization is commonly (although not exclusively) performed with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Successful aspirin desensitization induces a state of temporary tolerance to NSAIDs, which can be maintained indefinitely as long as the patient continues to take aspirin or another NSAID on a daily basis. This can be useful in several clinical scenarios. (See",
"      <a class=\"local\" href=\"#H13003361\">",
"       'Desensitization'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131280\">",
"    <span class=\"h2\">",
"     Contraindications to challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential that any concurrent cardiopulmonary conditions are under optimal control before a patient is challenged.",
"   </p>",
"   <p>",
"    In our clinic, we perform oral challenges on patients with asthma only if the pre-bronchodilator FEV1 is &ge;70 percent of the patient's best and &ge;1.5 L. The criteria for inhalation challenges are less stringent, as inhalational challenges induce milder reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003235\">",
"    <span class=\"h1\">",
"     TYPES OF CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Challenges to NSAIDs may be performed orally or via inhalation. Both types of challenges may be used in diagnosis and desensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131823\">",
"    <span class=\"h2\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is the drug most often utilized in oral challenges. There is more published experience with aspirin than any other NSAID, and aspirin has the additional advantage of not having been implicated in any confirmed cases of IgE-mediated anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131830\">",
"    <span class=\"h2\">",
"     Inhalational",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both bronchial and nasal inhalational protocols have been developed. Inhalational challenges result in milder symptoms than those provoked by oral challenge, presumably because there is less systemic absorption of the drug (although this has not been directly demonstrated).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      (Toradol&reg;) can be used [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. This is diluted in saline and administered intranasally.",
"     </li>",
"     <li>",
"      In other countries,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -lysine (ASA-lysine) solutions are available, which may be administered by bronchial or nasal inhalation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131837\">",
"    <span class=\"h1\">",
"     CHALLENGE PROTOCOLS AND PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003256\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected or known",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) are usually pretreated with leukotriene modifying drug (LTMDs) prior to undergoing a challenge or desensitization to NSAIDs, if the patient is not already taking one of these medications. If the patient is already taking an LTMD, then it is continued through the procedure.",
"   </p>",
"   <p>",
"    LTMDs significantly impact on the results of oral NSAID challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Before LTMDs became available, NSAID challenges were routinely performed in intensive care units because of the severe asthmatic and sometimes systemic symptoms (eg, hypotension) that could develop in highly sensitive patients. However, the recognition that LTMDs blunt the severity of NSAIDs pseudoallergic reactions has dramatically altered the way challenges are performed, such that many are now carried out in properly equipped outpatient settings.",
"   </p>",
"   <p>",
"    Large observational studies comparing patients challenged with LTMD premedication, compared to historical controls challenged without LTMD show that patients undergoing oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge while taking LTMDs demonstrate fewer and less severe episodes of bronchospasm, while nasal and ocular symptoms remain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. One study found that premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    resulted in a 90 percent reduction in asthmatic reactions to challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/7\">",
"     7",
"    </a>",
"    ]. The symptoms are essentially shifted from the lower airway to the upper airway. Montelukast and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    do not mask the reactions in oral challenges altogether, and symptoms are still detectable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/4\">",
"     4",
"    </a>",
"    ]. There is less experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    , and this agent may suppress symptoms to a greater degree. The effects of montelukast (10 mg and 40 mg) on nasal challenge were studied in a small randomized trial, and both doses reduced nasal symptoms by approximately one-third compared to placebo, with no difference between the two doses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following medications be administered prior to the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (10 mg once daily in adults) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      (20 mg twice daily in adults): The author&rsquo;s practice is to administer montelukast, either 10 mg daily beginning three days before OR 10 mg twice a day for one day before and then 10 mg daily on each day of the",
"      <span class=\"nowrap\">",
"       challenge/desensitization.",
"      </span>",
"     </li>",
"     <li>",
"      Extended release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      (1200 mg twice daily in adults): We administer this for at least three days prior to challenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical glucocorticoids taken regularly by the patient [including inhaled, intranasal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in combination with inhaled long-acting beta agonists (LABA)] should be continued throughout the procedure. In fact, it is the author&rsquo;s preference that patients with asthma are taking a combination inhaled",
"    <span class=\"nowrap\">",
"     steroid/LABA",
"    </span>",
"    medication at the time of the challenge. Systemic glucocorticoids, which have minimal effect on the outcome of challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/4\">",
"     4",
"    </a>",
"    ], are sometimes administered for a week or more before the challenge to optimize asthma control in patients with moderate to severe asthma.",
"   </p>",
"   <p>",
"    Premedication with antihistamines or cromolyn is not given. H1 antihistamines were shown to blunt reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/8\">",
"     8",
"    </a>",
"    ] and cromolyn was shown to delay the onset of symptoms in another [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003270\">",
"    <span class=\"h2\">",
"     Oral aspirin challenge and desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the author&rsquo;s center, over a thousand patients with AERD have been successfully challenged and desensitized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . The approach reviewed below is based upon that extensive clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003284\">",
"    <span class=\"h3\">",
"     Use of placebo doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not usually include placebos when a challenge is performed solely for the purposes of patient management. Particularly for patients suspected of having AERD, the index of suspicion for the condition is usually high based on history alone, and placebos are rarely needed.",
"   </p>",
"   <p>",
"    In contrast, placebo doses are",
"    <strong>",
"     essential",
"    </strong>",
"    in research studies in which challenge is performed for the purposes of confirming the diagnosis. Many protocols include an initial day in which only placebos are administered, to control for nonspecific changes in pulmonary function that can occur as the day progresses.",
"   </p>",
"   <p>",
"    There are some situations in which the use of placebo doses is clinically useful. As an example, placebo doses are helpful in the evaluation of the patient who is suspected of not having sensitivity to NSAIDs at all, in whom challenge is indicated to prove that the patient tolerates NSAIDs. We sometimes give such patients an initial dose of placebos, and also end the challenge with one or more placebo doses (so that the patient receives placebo when expecting the largest dose of the day) with one or more placebo doses in between. Informed consent should be obtained for the general inclusion of placebos, although the patient is obviously not told when in the protocol they will be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23255555\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sample oral challenge protocol used at our institution is provided (",
"    <a class=\"graphic graphic_table graphicRef70867 \" href=\"UTD.htm?43/46/44780\">",
"     table 1",
"    </a>",
"    ). This protocol uses commercially-available",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    tablets, with lower doses obtained by cutting an 81 mg tablet with a pill cutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/10\">",
"     10",
"    </a>",
"    ]. Doses are given at three hour intervals, up to a maximum dose of 325 mg. These protocols are carried out over one to two consecutive days.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A starting dose of 40.5 mg is suggested in most cases. This is based on a study in which 420 patients with AERD were challenged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and 75 percent reacted after a dose of 45 or 60 mg [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some experts suggest that the time interval between doses can be shortened to 90 minutes unless the patient specifically reports that symptoms began within 90 minutes after ingestion during past reactions. However, it is our clinical impression that a significant subset of patients with type 1 pseudoallergic reactions develops symptoms approximately two hours after administration. It is our practice to wait three hours between doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23255435\">",
"    <span class=\"h3\">",
"     Provocation of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria used to determine a positive oral challenge are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71124 \" href=\"UTD.htm?39/49/40731\">",
"     table 2",
"    </a>",
"    ). Most patients with AERD and pseudoallergic reactions to NSAIDs develop symptoms in response to a dose between 60 and 100 mg. As mentioned previously, premedication with a leukotriene modifying drug dramatically reduces the pulmonary symptoms seen during challenge, although nasal and ocular symptoms remain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20741443\">",
"    <span class=\"h4\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with positive respiratory reactions to oral challenge may be diagnosed with type 1 pseudoallergy. Patients with negative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenges either do not have type 1 pseudoallergy or, symptoms have been sufficiently blocked by leukotriene modifying medications as to not be apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/12\">",
"     12",
"    </a>",
"    ]. If the challenge was performed to diagnose type 1 pseudoallergy, then the procedure should be repeated without leukotriene modifying drugs. If the procedure was done to both diagnose and desensitize the patient to aspirin, a practical approach is to continue the patient on aspirin (650 mg twice daily) for up to three months. If the patient&rsquo;s symptoms have not substantially improved then either they do not have AERD or they are a non-responder to aspirin treatment and aspirin can be discontinued.",
"   </p>",
"   <p>",
"    Patients who develop cutaneous as well as respiratory symptoms may have type 4 pseudoallergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23255442\">",
"    <span class=\"h3\">",
"     Treatment of symptoms during challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment with LTMDs dramatically reduces the severity of symptoms, as mentioned previously. However, if symptoms do develop, they may last for several hours. Suggestions for management are based upon clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchospasm can be treated with nebulized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      as needed to relieve symptoms.",
"     </li>",
"     <li>",
"      Nasal obstruction can be treated with topical nasal decongestant sprays (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      ). Untreated nasal obstruction may lead to entrapment of secretions and severe headache. Oral antihistamines may also be helpful for nasal symptoms.",
"     </li>",
"     <li>",
"      Ocular symptoms may be treated with an oral antihistamine.",
"     </li>",
"     <li>",
"      Laryngospasm may be managed with nebulized racemic epinephrine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intramuscular epinephrine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14131852\">",
"    <span class=\"h2\">",
"     Inhalational challenge and desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries where ASA-lysine is available, the inhalational and nasal routes are preferred at most centers. In the United States, ASA-lysine is not available, but parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    may be used instead [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of",
"    <span class=\"nowrap\">",
"     nasal/bronchial",
"    </span>",
"    over oral provocation techniques include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Nasal/bronchial",
"      </span>",
"      challenges can be performed more quickly, increasing patient and clinician convenience.",
"     </li>",
"     <li>",
"      The symptoms induced by",
"      <span class=\"nowrap\">",
"       nasal/bronchial",
"      </span>",
"      challenges are more limited in nature and more quickly reversible relative to those induced by oral challenges.",
"     </li>",
"     <li>",
"      Nasal administration is safe in patients who have an FEV1 &lt;1.5 L and therefore are not good candidates for oral or bronchial provocative challenge. However, nasal administration cannot be performed in patients with severe or complete nasal obstruction due to severe polyposis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose, means of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    instillation, duration of observation period, and criteria for positivity are different with these protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ]. Patients undergoing bronchial provocation challenges should NOT be pretreated with leukotriene modifiers, as this could blunt symptoms enough to render the procedure non-diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23255278\">",
"    <span class=\"h3\">",
"     Ketorolac nasal provocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AERD can also be diagnosed using challenge with an intranasal solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    , instead of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . This approach was studied in 100 patients with pseudoallergic reactions that were previously confirmed by oral aspirin challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients received incrementally increasing doses of intranasal ketorolac at 30 minute intervals and were then switched to oral aspirin at three hour intervals to complete the challenge and reach the full dose of 325 mg (",
"    <a class=\"graphic graphic_table graphicRef67707 \" href=\"UTD.htm?6/22/6508\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1360407\">",
"    <span class=\"h4\">",
"     Definition of a positive nasal challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive nasal challenge was defined as any nasal-ocular symptoms consistent with conjunctivitis or rhinitis or a decrease in nasal flow rate &ge;20 percent, or any lower airways signs and symptoms, including bronchospasm with a decrease in FEV1 &ge;15 percent, or laryngospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/2\">",
"     2",
"    </a>",
"    ]. In the study of 100 patients mentioned above, the average provoking dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    was a cumulative dose of 12.1 mg, and patients most often reacted after the third or fourth dose of the intranasal portion of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23255285\">",
"    <span class=\"h3\">",
"     Aspirin-lysine bronchial provocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial provocation with ASA-lysine (not licensed in the US) involves inhaling increasing doses of ASA-lysine at 30 minute intervals. As with other challenges, the patient's asthma should be controlled before beginning the challenge (ie, forced expiratory volume in the first second (FEV1) should be &ge;70 percent of the patient's best value when feeling well and &ge;1.5 L).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23255299\">",
"    <span class=\"h4\">",
"     Definition of a positive inhalational challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive bronchospastic response is defined as a drop in FEV1 &ge;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Bronchospasm is usually the only type of response elicited, occurs fairly quickly (around 20 minutes), and is easily reversible with inhaled beta agonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003298\">",
"    <span class=\"h2\">",
"     Comparison of oral and inhalational challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both oral and inhalational challenges with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may be used to diagnosis AERD, but only oral challenges have been used as a means of desensitizing both the upper and lower airways for patients who require long-term oral aspirin therapy.",
"   </p>",
"   <p>",
"    For the purpose of diagnosis, oral challenges are slightly more sensitive. There have been a small number of well-designed studies comparing oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge to bronchial ASA-lysine provocation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study performed both oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and bronchial ASA-lysine provocation in 22 patients suspected of having AERD [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/16\">",
"       16",
"      </a>",
"      ]. Both protocols detected bronchospastic reactions in the same subset of patients, although bronchial inhalation produced limited and shorter bronchospastic reactions that were more easily treated. However, 2 of the 22 patients who underwent oral aspirin challenge had solely naso-ocular symptoms and neither of these individuals reacted to the bronchial ASA-lysine challenge, which is not unexpected since the bronchial challenge provides no direct contact to the naso-ocular surfaces.",
"     </li>",
"     <li>",
"      Another study evaluated 35 patients who were already diagnosed with AERD (by clinical history and past positive oral provocation test by the FEV1 &ge;20 percent criterion), and re-challenged them with either oral or bronchial provocation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/17\">",
"       17",
"      </a>",
"      ]. This study utilized a higher cumulative dose of inhaled ASA-lysine than the previous study and a modified oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      challenge protocol. They demonstrated a higher sensitivity (89 percent versus 77 percent) and similar specificity (93 percent in both groups) in the oral aspirin challenge versus the bronchial ASA-lysine provocation. Three patients had a positive oral aspirin challenge (defined by a decrease in FEV &ge;20 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extrabronchial symptoms) but a negative bronchial provocation challenge. One of these individuals had a sudden 40 percent drop in FEV1 and the other two had only extrabronchial symptoms during the oral aspirin challenge.",
"     </li>",
"     <li>",
"      A third study evaluated 100 patients known to have AERD (by clinical history and past positive oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      challenge) and re-challenged them with intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      (at 30 minute intervals) followed by oral aspirin with a traditional oral aspirin protocol [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients undergoing nasal ketorolac challenge experienced a smaller decrease in FEV1 (9 versus 13 percent drop) and a reduced incidence of extrapulmonary symptoms (23 versus 45 percent) compared to those undergoing standard oral aspirin challenge. In addition, nasal challenge patients achieved desensitization to NSAIDs more rapidly (1.9 versus 2.6 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the inhalational challenges can fail to detect patients with very mild symptoms. Oral challenges induce more extensive bronchospasm, although pulmonary symptoms may be reduced or eliminated by pretreatment with leukotriene modifying drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003361\">",
"    <span class=\"h1\">",
"     DESENSITIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID desensitization is a process of inducing tolerance to NSAIDs in a patient with pseudoallergic reactions. The drug must be taken regularly following desensitization, since tolerance is lost if exposure is interrupted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194804669\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AERD, the indications for NSAID desensitization include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic rhinosinusitis with nasal polyposis that is refractory to topical glucocorticoids and other therapies. The impact of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy on asthma is less clear. (See",
"      <a class=\"local\" href=\"#H14035446\">",
"       'Efficacy of aspirin therapy in AERD'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The need for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      antiplatelet therapy in patients with cardiovascular risk factors or confirmed cardiovascular disease.",
"     </li>",
"     <li>",
"      The need for NSAIDs to treat chronic inflammatory conditions, such as arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility and limitations of NSAID desensitization are reviewed here. A more general discussion of the management of the different types of NSAID reactions, including treatment with highly selective COX-2 inhibitors or with very weak COX-1 inhibitors, is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003375\">",
"    <span class=\"h2\">",
"     Protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization of patients with pseudoallergic NSAID reactions involves extending the challenge procedure used for diagnosis. Once the patient has developed symptoms and these have been treated, the challenge is resumed by repeating the same dose that elicited the reaction. If there is another reaction, the symptoms are again treated and the same dose is given again until there is no further reaction. Once the patient no longer reacts to that dose, the protocol is continued until the patient has ingested a full 325 mg dose without developing symptoms. At this point, the patient is desensitized. AERD patients who have been successfully desensitized to 325 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    can subsequently increase the dose themselves at home. We believe this approach to be safe because in over 600 consecutive desensitizations to aspirin, we have not seen a reaction to 650 mg of aspirin once a patient is desensitized to 325 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of whether to repeat the provoking dose in patients with mild reactions, rather than simply continuing the protocol with the next higher dose, has not been investigated. Thus, this approach cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003382\">",
"    <span class=\"h2\">",
"     Outcomes of desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with AERD can be desensitized to NSAIDs. In response to chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, patients with AERD can experience improvements in both asthma and chronic rhinosinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14034612\">",
"    <span class=\"h3\">",
"     Cross-desensitization to other NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AERD who successfully complete an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    desensitization will also tolerate other NSAIDs and can use them as needed, as long as they continue to take 325 mg of aspirin or the equivalent of another COX-1 inhibiting NSAID daily to maintain the desensitized state [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/19\">",
"     19",
"    </a>",
"    ]. As an example, a patient with AERD who has been desensitized to 325 mg of aspirin twice daily should be able to take 600 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    for a headache if needed, without developing symptoms. A desensitized patient can also change from one NSAID to another without losing tolerance. For example, a patient taking 650 mg of aspirin twice daily could discontinue this and immediately begin taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    sodium for an inflammatory condition instead. This applies to all patients with pseudoallergic reactions who have been desensitized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003389\">",
"    <span class=\"h3\">",
"     Missed doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is interrupted in a patient with AERD who was previously desensitized, there is a \"refractory period\" of at least two to three days before they become reactive again. During this period, ASA or the desired NSAID can be reintroduced without a reaction. Also, the return to sensitivity is gradual, so even if three to five days have elapsed, one can reintroduce the 325 mg dose (or 81 mg if desired as treatment) in the",
"    <span class=\"nowrap\">",
"     office/clinic",
"    </span>",
"    without the patient experiencing the severity of the reaction they had to their provoking dose during the initial challenge. Beyond five days, the full challenge and desensitization process must be repeated before the patient can resume NSAID therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14034627\">",
"    <span class=\"h3\">",
"     Breakthrough symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, a patient reports recurrent symptoms and appears to have lost tolerance. It is our clinical experience that this is almost always due to some other asthma trigger, such as an upper respiratory tract infection, GERD, or irritant exposure. The patient may inappropriately attribute this to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and stop taking it. Patients should be counseled that they will remain tolerant to aspirin as long as they are compliant with the daily dose. They may still experience flares in their asthma and rhinitis symptoms from time to time, but provided they have been compliant, they should not attribute these changes to the aspirin or discontinue it without speaking to their clinician first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14035446\">",
"    <span class=\"h1\">",
"     EFFICACY OF ASPIRIN THERAPY IN AERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy can reduce upper and lower airway symptoms in patients with AERD, as demonstrated one small randomized trial and several larger uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/20-28\">",
"     20-28",
"    </a>",
"    ]. The effects on rhinosinusitis symptoms are usually more dramatic than the pulmonary effects. It typically takes at least three months to see the effects of therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized crossover trial of 25 patients with AERD, subjects were desensitized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and then treated with daily aspirin or placebo for three months, and then crossed over to the other intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients receiving aspirin had significant improvement in nasal symptoms and use of nasal medications. Approximately one-half experienced improvements in asthma symptoms, although these changes did not reach statistical significance.",
"     </li>",
"     <li>",
"      An uncontrolled study examined 65 patients with AERD, already receiving optimal medical management, who were desensitized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and received daily treatment for one to six years (mean of three years) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/24\">",
"       24",
"      </a>",
"      ]. Doses ranged from 325 mg once daily to 650 mg three times daily, with a mean dose of about 1200 mg daily. Clinical outcomes were analyzed before desensitization and after varying periods of aspirin treatment. Those taking aspirin experienced significant reductions in the numbers of sinus infections per year (median reduction was from six episodes to two), hospitalizations for treatment of asthma per year, improvement in olfaction, and reduction in use of systemic glucocorticoids. The need for sinus",
"      <span class=\"nowrap\">",
"       surgery/polypectomy",
"      </span>",
"      was decreased from an average of one surgery every 3 years, to one every 10 years. In contrast, emergency department visits for asthma and use of inhaled glucocorticoids were unchanged.",
"     </li>",
"     <li>",
"      Another study followed 172 patients with AERD who were desensitized to and treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at a referral center, and then discharged back to their original providers and followed with interviews [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/26\">",
"       26",
"      </a>",
"      ]. The mean daily dose of aspirin was 1138 mg daily. By the first six months of aspirin treatment, there were significant reductions in the number of sinus infections and need for oral glucocorticoids, and improvements in both",
"      <span class=\"nowrap\">",
"       nasal/sinus",
"      </span>",
"      and asthma symptoms. Of the 126 patients who completed a year or more of aspirin treatment, 87 percent experienced a good to excellent response. Mean",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses decreased at six months and one year.",
"      <br/>",
"      <br/>",
"      The remaining 13 percent of patient did not experience noticeable improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/26\">",
"       26",
"      </a>",
"      ]. Most of these patients had concomitant forms of chronic sinusitis in addition to AERD. For example, some were sensitized to perennial allergens and were generally neither avoiding these allergens nor receiving immunotherapy. Others had severe gastroesophageal reflux disease (GERD), allergic fungal sinusitis, or other co-existing conditions that would not be expected to be altered by aspirin. Fourteen percent of patients discontinued aspirin because of various known side effects (mostly gastrointestinal intolerance).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1360083\">",
"    <span class=\"h2\">",
"     Optimal aspirin dose for AERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that both 325 mg twice daily and 650 mg twice daily are effective in reducing",
"    <span class=\"nowrap\">",
"     nasal/sinus",
"    </span>",
"    and asthma symptoms in patients with AERD. An analysis of 137 patients with AERD referred to the Scripps Clinic and treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for at least one year, found approximately one-half could successfully decrease the dose from 650 mg twice daily to 325 mg twice daily without a relapse of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the other half required the higher dose to maintain improvement long-term. Only occasional patients derived lasting benefit from 325 mg once daily.",
"   </p>",
"   <p>",
"    The lowest effective dose is not precisely defined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the randomized trial discussed previously, most subjects began to develop recurrence of their nasal congestion when the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      dose was reduced below 325 mg twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent unblinded study sought to determine if even lower doses could be effective, by comparing 100 mg and 300 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      daily [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/23\">",
"       23",
"      </a>",
"      ]. After one year, there was no improvement in asthma, and polyps recurred in the group receiving the lower dose, and all patients were changed to 300 mg of aspirin daily. A subsequent cohort of 39 patients was evaluated, and each completed at least a year of aspirin therapy. Nasal polyposis significantly decreased in all patients. Asthma symptoms were not evaluated. Thus, 300 mg daily appears to be helpful for the management of nasal polyposis, although the benefit on asthma symptoms is not as clear. In contrast, a dose of 100 mg daily is clearly not sufficient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, both 325 mg twice daily and 650 mg twice daily are effective in reducing",
"    <span class=\"nowrap\">",
"     nasal/sinus",
"    </span>",
"    and asthma symptoms in patients with AERD. Because approximately equal percentages of patients tolerate each of these doses, but one-half clearly benefit only from the higher dose, it is logical to begin therapy at the higher dose. The effects should be apparent after three to six months of therapy, after which patients who have responded well could have their doses reduced to the lowest dose that maintains symptom control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/27\">",
"     27",
"    </a>",
"    ]. If symptoms begin to escalate again on the lower dose, then patients should resume 650 mg twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14035453\">",
"    <span class=\"h2\">",
"     Other issues of aspirin dosing after desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial dose of 650 mg twice daily is the recommended for the treatment of AERD. Patients who have been desensitized to 325 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    can increase their dose to 650 mg twice daily on their own, and medical supervision of the dose escalation is not required.",
"   </p>",
"   <p>",
"    Other issues of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    dosing after desensitization include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AERD who wish to use other NSAIDs intermittently (eg, for musculoskeletal pain, headaches, or dysmenorrhea) should take at least 325 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      daily to maintain the desensitized state, as mentioned previously. (See",
"      <a class=\"local\" href=\"#H14034612\">",
"       'Cross-desensitization to other NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with AERD who wish to take 81 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      daily for cardioprotection will remain tolerant of this low dose of aspirin, although they will NOT be able to tolerate larger doses of aspirin or be cross-desensitized to other NSAIDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1360236\">",
"    <span class=\"h2\">",
"     Prevention of gastrointestinal toxicity from NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians prescribing chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy should discuss the risk of gastrointestinal toxicity with patients and assess the patient&rsquo;s baseline risk of this complication before initiating therapy. Primary prevention of gastrointestinal toxicity is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14035759\">",
"    <span class=\"h2\">",
"     Reasons for discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of gastric irritation from daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is reported by up to one-half of patients, although not all of these patients have symptoms severe enough to cause them to stop therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Still, gastric irritation is the most common reason for discontinuing therapy. In the author&rsquo;s experience, this appears to occur at similar rates in patients taking 325 mg twice daily and 650 mg twice daily. However, published data relating NSAID dose to gastritis and GI bleeding are inconsistent, and other risk factors may be more important than dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small number of patients presenting with either acute or chronic epigastric pain in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, with or without nausea, have been found to have pancreatitis, as evidenced by elevations in serum lipase and amylase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, it is not entirely clear that aspirin was the cause in these cases.",
"   </p>",
"   <p>",
"    Other reasons for discontinuation include pregnancy (in the third trimester) and elective surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18281/abstract/26\">",
"     26",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and NSAIDs during pregnancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'NSAIDs and aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003417\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease (AERD) may develop type I pseudoallergic reactions to NSAIDs (including aspirin). NSAID challenges are used to confirm the diagnosis of pseudoallergy. These same challenges can be extended to achieve desensitization to NSAIDs. NSAID desensitization allows patients with AERD and type I pseudoallergy to safely take any NSAID. Desensitization may be indicated for one of several reasons, including treatment of rheumatologic disorders, pain management or antiplatelet therapy. Chronic aspirin therapy is also used to treat the upper and lower respiratory manifestations of AERD. (See",
"      <a class=\"local\" href=\"#H14131255\">",
"       'Indications for challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, NSAID challenge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      desensitization should be performed by an allergy specialist with experience in diagnosing and managing drug adverse reactions. (See",
"      <a class=\"local\" href=\"#H14131689\">",
"       'Referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14131210\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both oral and inhalational (either nasal or bronchial) NSAID challenge procedures have been developed for diagnosing pseudoallergy reactions to NSAIDs. However, only oral protocols have been used for desensitization:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      <span class=\"nowrap\">",
"       challenge/desensitization",
"      </span>",
"      has been the approach in the United States (US) (",
"      <a class=\"graphic graphic_table graphicRef70867 \" href=\"UTD.htm?43/46/44780\">",
"       table 1",
"      </a>",
"      ), although an inhalational protocol that uses a liquid preparation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      has been developed (",
"      <a class=\"graphic graphic_table graphicRef67707 \" href=\"UTD.htm?6/22/6508\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In Europe, a liquid preparation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -lysine has been available for decades and most challenges are performed by inhalation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAID challenge procedures are expected to provoke symptoms, and the development of characteristic signs and symptoms confirms the diagnosis of a type 1 pseudoallergic reaction (",
"      <a class=\"graphic graphic_table graphicRef71124 \" href=\"UTD.htm?39/49/40731\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13003235\">",
"       'Types of challenges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients with AERD be premedicated with a leukotriene modifying agent before oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      <span class=\"nowrap\">",
"       challenge/desensitization",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      is commonly given in this setting. (See",
"      <a class=\"local\" href=\"#H13003256\">",
"       'Premedication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desensitization is accomplished by continuing the diagnostic challenge procedure. Symptoms are provoked and treated, and the provoking dose is then repeated until the patient no longer reacts to it. The patient is considered desensitized when 325 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is tolerated. Aspirin desensitization is nearly always successful in patients with AERD. (See",
"      <a class=\"local\" href=\"#H13003361\">",
"       'Desensitization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once desensitized, patients must take at least 325 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      daily to maintain the desensitized state. They are also cross-desensitized to other NSAIDs and can take these medications as well. However, if the dose of aspirin is reduced to 81 mg a day, cross-desensitization is usually lost. (See",
"      <a class=\"local\" href=\"#H13003382\">",
"       'Outcomes of desensitization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with AERD and CRS with nasal polyposis who have nasal symptoms that are worsening despite leukotriene modifying agents, topical glucocorticoids, and other appropriate therapies, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      desensitization followed by daily aspirin therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to treat AERD, we usually start with an aspirin dose of 650 mg twice daily. We evaluate the patient&rsquo;s response to therapy after three months. If symptoms are improved after three months, the dose may be lowered to 325 mg twice daily. (See",
"      <a class=\"local\" href=\"#H14035446\">",
"       'Efficacy of aspirin therapy in AERD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/1\">",
"      White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006; 97:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/2\">",
"      Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/3\">",
"      Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/4\">",
"      White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005; 95:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/5\">",
"      Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002; 32:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/6\">",
"      Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 2004; 24:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/7\">",
"      Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000; 85:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/8\">",
"      Szczeklik A, Serwonska M. Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine. Thorax 1979; 34:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/9\">",
"      Dahl R. Oral and inhaled sodium cromoglycate in challenge test with food allergens or acetylsalicylic acid. Allergy 1981; 36:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/10\">",
"      Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007; 98:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/11\">",
"      Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009; 123:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/12\">",
"      Morwood K, Gillis D, Smith W, Kette F. Aspirin-sensitive asthma. Intern Med J 2005; 35:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/13\">",
"      Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998; 101:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/14\">",
"      Alonso-Llamazares A, Martinez-C&oacute;cera C, Dom&iacute;nguez-Ortega J, et al. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002; 57:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/15\">",
"      Bianco S, Robuschi M, Petrigni G. Aspirin-induced tolerance in aspirin induced asthma detected by a new challenge technique. IRCS J Med Sci 1977; 5:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/16\">",
"      Dahl&eacute;n B, Zetterstr&ouml;m O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J 1990; 3:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/17\">",
"      Nizankowska E, Besty��ska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15:863.",
"     </a>",
"    </li>",
"    <li>",
"     The Scripps Clinic, San Diego, California. Dr. Simon may be reached at simon.ronald@scrippshealth.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/19\">",
"      Mathison DA, Lumry WR, Stevenson DD, et al. Aspirin in chronic urticaria and/or angioedema: Studies of sensitivity and desensitization. J Allergy Clin Immunol 1982; 69:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/20\">",
"      Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/21\">",
"      Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/22\">",
"      Williams AN, Woessner KM. The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. Curr Allergy Asthma Rep 2008; 8:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/23\">",
"      Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008; 63:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/24\">",
"      Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/25\">",
"      McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol 2006; 20:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/26\">",
"      Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/27\">",
"      Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/28\">",
"      Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007; 119:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/29\">",
"      Hoyte FC, Weber RW, Katial RK. Pancreatitis as a novel complication of aspirin therapy in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2012; 129:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18281/abstract/30\">",
"      Stevenson DD, White AA, Simon RA. Aspirin as a cause of pancreatitis in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2012; 129:1687.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15539 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18281=[""].join("\n");
var outline_f17_54_18281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13003417\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14130927\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131015\">",
"      Pseudoallergic NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13003220\">",
"      OVERVIEW OF NSAID CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131689\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131210\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131255\">",
"      Indications for challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131280\">",
"      Contraindications to challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13003235\">",
"      TYPES OF CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131823\">",
"      Oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131830\">",
"      Inhalational",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14131837\">",
"      CHALLENGE PROTOCOLS AND PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13003256\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13003270\">",
"      Oral aspirin challenge and desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13003284\">",
"      - Use of placebo doses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23255555\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23255435\">",
"      - Provocation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20741443\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23255442\">",
"      - Treatment of symptoms during challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14131852\">",
"      Inhalational challenge and desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23255278\">",
"      - Ketorolac nasal provocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1360407\">",
"      Definition of a positive nasal challenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23255285\">",
"      - Aspirin-lysine bronchial provocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23255299\">",
"      Definition of a positive inhalational challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13003298\">",
"      Comparison of oral and inhalational challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13003361\">",
"      DESENSITIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194804669\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13003375\">",
"      Protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13003382\">",
"      Outcomes of desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14034612\">",
"      - Cross-desensitization to other NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13003389\">",
"      - Missed doses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14034627\">",
"      - Breakthrough symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14035446\">",
"      EFFICACY OF ASPIRIN THERAPY IN AERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1360083\">",
"      Optimal aspirin dose for AERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14035453\">",
"      Other issues of aspirin dosing after desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1360236\">",
"      Prevention of gastrointestinal toxicity from NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14035759\">",
"      Reasons for discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13003417\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/46/44780\" title=\"table 1\">",
"      ASA challenges AERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/49/40731\" title=\"table 2\">",
"      Resp rxns during ASA chal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/22/6508\" title=\"table 3\">",
"      Nasal challenge protocol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_54_18282="Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation";
var content_f17_54_18282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18282/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18282/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/54/18282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/54/18282/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/54/18282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Potential complications include anemia, hypercalcemia, renal insufficiency, infection, and skeletal lesions.",
"   </p>",
"   <p>",
"    When multiple myeloma is suspected, the diagnosis must be carefully verified. For example, patients who have 10 percent or more clonal plasma cells in the marrow but no evidence of end organ damage that can be attributed to the plasma cell disorder (smoldering multiple myeloma) do not require therapy because there is no proof of clear benefit with currently available therapies and some of these patients remain stable without treatment over extended periods of time. An exception is that patients with &ge;60 percent clonal plasma cells in the bone marrow who lack end-organ damage are also considered as having MM and are candidates for initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H2#H2\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Verification of the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of multiple myeloma requires the presence of end organ damage (hypercalcemia, renal failure, anemia, or bone disease) that is thought to be related to the plasma cell proliferative disorder. Once the diagnosis of multiple myeloma is confirmed, the next step includes testing for those abnormalities that help predict outcome following treatment. Individual cases are stratified into either high risk or standard risk multiple myeloma based upon the results of FISH for specific translocations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deletions, conventional cytogenetics, and the plasma cell labeling index. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following diagnosis and risk stratification, patients need to be assessed to determine eligibility for hematopoietic cell transplantation (HCT). When compared with chemotherapy alone, intensified chemotherapy followed by HCT appears to prolong both event-free and overall survival in previously untreated patients with standard risk myeloma. The initial chemotherapy given to patients who are candidates for HCT should limit agents that may impair stem cell collection. As such, the initial chemotherapy given to patients eligible for HCT differs from that given to patients who are ineligible.",
"   </p>",
"   <p>",
"    The initial chemotherapy for patients with symptomatic standard risk and intermediate risk multiple myeloma who are candidates for HCT is discussed here. General treatment indications, risk stratification, and the choice of initial treatment options are reviewed separately. In addition, the initial chemotherapy options for patients with high risk multiple myeloma and patients who are not candidates for HCT is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discussions of relapsed or resistant myeloma, the treatment of complications of multiple myeloma (eg, hypercalcemia, renal insufficiency, skeletal lesions), and the use of bisphosphonates are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"     \"Treatment of the complications of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDUCTION CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are candidates for hematopoietic cell transplantation (HCT), induction chemotherapy is administered for two to four months prior to stem cell collection in order to reduce the number of tumor cells in the bone marrow and peripheral blood, lessen symptoms, and mitigate end-organ damage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/1\">",
"     1",
"    </a>",
"    ]. During this time, specific arrangements for the subsequent HCT can be made to ease the transition of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among transplant candidates, a variety of different regimens have been studied. Our approach to treatment is consistent with that proposed by the International Myeloma Working Group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/2\">",
"     2",
"    </a>",
"    ]. Our preferred initial treatment for patients with multiple myeloma who are candidates for transplantation depends on the baseline risk stratification (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For standard risk patients who are candidates for HCT, our preferred treatment options are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (Rd) (",
"      <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"       table 1",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and dexamethasone (VCd) (",
"      <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"       table 2",
"      </a>",
"      ). For most patients, we suggest initial treatment with Rd rather than VCd. This preference places a high value on the relatively low toxicity of this regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For intermediate risk patients who are candidates for HCT, we recommend initial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen. We prefer VCd. These patients were previously considered to have high risk disease, but treatment with bortezomib-containing regimens have resulted in outcomes approaching that of standard risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"       \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For high risk patients who are candidates for HCT, we suggest initial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen, such as bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VRd). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"       \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These preferred treatment options have not been compared directly with each other in a randomized trial in these patient populations. Data supporting their use come largely from single arm trials or randomized trials comparing these regimens with other regimens. As such, the choice among initial treatment regimens should take into consideration physician preference, risk of neuropathy, risk of thrombosis, and the patient&rsquo;s underlying renal function.",
"   </p>",
"   <p>",
"    In contrast, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    has been associated with damage to the hematopoietic stem cell compartment as well as an increased risk of myelodysplasia following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a prospective study of peripheral blood progenitor cell (PBPC) collection that included 100 patients found that fewer patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    were able to meet minimal criteria for collection of adequate numbers of stem cells to allow high dose chemotherapy followed by reinfusion of highly-purified CD34+ hematopoietic stem cells (30 versus 80 percent) when compared with patients who had not received melphalan [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who have received long-term melphalan-based chemotherapy, or those that have refractory multiple myeloma after extensive therapy, are generally unable to mobilize sufficient \"high quality\" stem cells to allow successful transplantation; this may be especially important in patients over the age of 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As such, among patients with symptomatic multiple myeloma who are candidates for autologous HCT, we recommend avoiding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -containing regimens as induction chemotherapy.",
"   </p>",
"   <p>",
"    After stem cell collection, patients either proceed to early (upfront) autologous HCT or can opt for delayed autologous HCT at the time of relapse. Overall survival in one study was similar between early versus delayed HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/8\">",
"     8",
"    </a>",
"    ]. The factors that influence the decision between early versus delayed HCT include patient preference, patient age (as age approaches 70, early transplantation is preferred), response and tolerability to the initial chemotherapy regimen, insurance approval (some insurers do not cover stem cell harvest and cryopreservation without immediate transplantation) and whether centers have the facilities and resources for long-term storage of stem cells. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H5#H5\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Timing of HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lenalidomide with dexamethasone (Rd)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (Rd) is our preferred initial therapy for patients who are candidates for HCT, since therapy is highly effective and well tolerated (",
"    <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"     table 1",
"    </a>",
"    ). An acceptable alternative, if lenalidomide is not available, is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and dexamethasone (VCd) (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4997358\">",
"     'Bortezomib, cyclophosphamide, dexamethasone (VCd)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We recommend low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , rather than standard dose dexamethasone, when administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , since lower doses are associated with improved survival and lower toxicity. Studies supporting the use of lenalidomide and dexamethasone are summarized below. Further trials of lenalidomide plus dexamethasone based regimens are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rd versus TD &mdash; There are no randomized trials comparing Rd with TD. These regimens were compared in a retrospective single-institution series of 411 consecutive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/10\">",
"       10",
"      </a>",
"      ]. The Rd combination was associated with a higher response rate than TD (at least partial response 80 versus 61 percent), as well as longer time to progression, progression-free survival, and overall survival (27 versus 17 months, 27 versus 17 months, and median not reached versus 57 months, respectively).",
"      <br/>",
"      <br/>",
"      Toxicity profiles differed significantly in the two regimens. For the Rd regimen, the main grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      toxicity was neutropenia (14.6 versus 0.6 percent with TD). In contrast, the main toxicities with TD were thromboembolism and peripheral neuropathy (15 versus 9 and 10 versus 0.9 percent, respectively compared with Rd).",
"     </li>",
"     <li>",
"      Rd versus",
"      <span class=\"nowrap\">",
"       placebo/dex",
"      </span>",
"      &mdash; A phase III randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      versus placebo plus high-dose dexamethasone in 192 patients with newly diagnosed MM was closed early due to safety concerns of high dose dexamethasone when combined with lenalidomide (as described below) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/11\">",
"       11",
"      </a>",
"      ]. Rd resulted in superior rates of overall response (78 versus 48 percent), very good partial response (63 versus 16 percent), and one-year progression-free survival (78 versus 52 percent), but similar rates of survival at one year (94 versus 88 percent). Rd was associated with higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (21 versus 5 percent) and thromboembolic events (24 versus 5 percent) despite prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Low-dose versus high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      &mdash; In a phase III trial conducted by the Eastern Cooperative Oncology Group (E4A03), 445 previously untreated patients with multiple myeloma were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus \"standard\" high dose dexamethasone (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by mouth on days 1 to 4, 9 to 12, and 17 to 20 of each cycle) versus lenalidomide plus lower dose dexamethasone (40 mg by mouth on days 1, 8, 15, and 22 of each 28-day cycle) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/12\">",
"       12",
"      </a>",
"      ]. The trial was stopped prematurely by the data safety monitoring committee because mortality was increased in the high-dose dexamethasone arm.",
"      <br/>",
"      <br/>",
"      The use of low-dose dexamethasone had the following significant benefits when compared with \"standard\" high dose dexamethasone:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased survival at both one and two years (96 versus 87 percent and 87 versus 75 percent, respectively). This survival advantage was seen in patients &lt;65 years of age as well as for those &ge;65 years of age. This one-year survival is the highest yet obtained in any phase III trial in patients with newly diagnosed myeloma.",
"     </li>",
"     <li>",
"      Less toxicity, including a lower rate of deep vein thrombosis or pulmonary embolus (12 versus 26 percent) and a lower incidence of infection or pneumonia (9 versus 16 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these observations, the lower",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    dose (eg, 40 mg by mouth on days 1, 8, 15, and 22 of each 28-day cycle) is now used for all newly diagnosed patients with myeloma who are receiving dexamethasone alone or in combination (eg, dexamethasone, TD, Rd), except perhaps in myeloma-induced renal failure, where rapid reduction in light chain production is critical [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/13\">",
"     13",
"    </a>",
"    ]. All cooperative group phase III clinical trials being planned or conducted have also reduced the dose of dexamethasone to 40 mg once per week based on these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    25 mg by mouth daily for 21 days of a 28-day treatment cycle along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    40 mg by mouth once per week of each 28-day cycle (",
"    <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"     table 1",
"    </a>",
"    ). Lenalidomide has boxed warnings for hematologic toxicities, thromboembolism, and birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/14\">",
"     14",
"    </a>",
"    ]. In the United States, the use of lenalidomide is subject to the RevAssist program (www.REVLIMID.com) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects. Patients with renal insufficiency experience more neutropenia with the use of lenalidomide [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/15\">",
"     15",
"    </a>",
"    ]. Its use in patients with renal impairment and options for thromboembolism prophylaxis are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H32#H32\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be noted that administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    has been associated with difficulties in collecting adequate numbers of peripheral blood stem cells in some patients when mobilization is attempted using growth factor alone. Stem cells in such patients can usually be harvested using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus growth factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bortezomib regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    has also been used alone or in combination with other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) in previously untreated patients and produces high response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/17-27\">",
"     17-27",
"    </a>",
"    ]. It is particularly useful in patients with renal failure and those with high risk features. Frequent toxicities included sensory neuropathy (64 percent), constipation (53 percent), nausea (53 percent), and fatigue (44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/20\">",
"     20",
"    </a>",
"    ]. Bortezomib can be administered intravenously or subcutaneously (SC) and, in general, SC is preferred due to a lower risk of neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H17#H17\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Treatment of high risk myeloma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no randomized data demonstrating superiority over either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VD) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus dexamethasone (Rd), the bortezomib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and dexamethasone (VCd) and bortezomib plus lenalidomide and dexamethasone (VRd) regimens are commonly being used as initial therapy in the United States. VD requires a twice-weekly bortezomib schedule, which is associated with a high risk of grade 3 or higher peripheral neuropathy. In contrast, the addition of cyclophosphamide or lenalidomide permits a weekly dosing of bortezomib in the VCd and VRd regimens. (See",
"    <a class=\"local\" href=\"#H4997358\">",
"     'Bortezomib, cyclophosphamide, dexamethasone (VCd)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2236472\">",
"    <span class=\"h3\">",
"     Bortezomib plus dexamethasone (VD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase II trial examined the use of six cycles of alternating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VD) followed by autologous hematopoietic cell transplantation (HCT) in the treatment of 40 newly diagnosed, previously untreated patients with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/28\">",
"     28",
"    </a>",
"    ]. The overall response rate before HCT was 65 percent with the majority of responses occurring within the first two cycles of treatment. The overall response rate after HCT was 88 percent with 33 percent complete responses and 22 percent very good partial responses (VGPRs). Toxicity was mild.",
"   </p>",
"   <p>",
"    A phase III trial randomly assigned therapy with VD or VAD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [adriamycin],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) as induction therapy prior to autologous HCT in 482 patients with newly diagnosed multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/29\">",
"     29",
"    </a>",
"    ]. VD resulted in significantly higher response rates and a trend toward longer progression-free survival. No improvement in overall survival was seen. This study shows that superior VGPR and complete response (CR) rates may not translate into meaningful improvements in progression-free or overall survival, and it illustrates the limitations of CR and VGPR as surrogate endpoints in myeloma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4997358\">",
"    <span class=\"h3\">",
"     Bortezomib, cyclophosphamide, dexamethasone (VCd)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VCd, also called CyBorD) is one of our preferred treatment options for patients with newly diagnosed multiple myeloma (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a phase II trial (EVOLUTION trial), 140 patients with newly diagnosed MM were randomly assigned to receive initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (VRd),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (VCd), or both (VDCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/26\">",
"     26",
"    </a>",
"    ]. After an interim analysis, the protocol was amended to change the VCd regimen to include an additional dose of cyclophosphamide (VCd-mod). Following four cycles of therapy, overall response rates were 73, 63, 82, and 80 percent in patients who received VRd, VCd, VCd-mod, and VDCR, respectively. Corresponding rates of very good partial response or better were 32, 13, 41, and 33 percent. Approximately 88 percent of patients receiving VCd-mod experienced at least one severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicity with the most common being neutropenia (24 percent), neuropathy (18 percent), and anemia (12 percent). &nbsp;",
"   </p>",
"   <p>",
"    The dosing schedule for VCd used in practice is a modification of that used in clinical trials in order to reduce neurotoxicity and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    -related toxicity. We typically use a weekly dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and dexamethasone 40 mg (",
"    <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"     table 2",
"    </a>",
"    ). Treatments are repeated weekly or three weeks out of four as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/3\">",
"     3",
"    </a>",
"    ]. The weekly schedule minimizes the risk of neuropathy.",
"   </p>",
"   <p>",
"    VCd is administered with antiviral prophylaxis such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    400 mg twice daily throughout treatment. Some clinicians also administer prophylaxis with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    on Monday, Wednesday, and Friday of each week for prevention of Pneumocystis infection. For patients with moderate or severe impairment of hepatic function (serum bilirubin &ge;1.5 times the upper limit of normal), we initiate therapy with a reduced dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    (0.7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2236493\">",
"    <span class=\"h3\">",
"     Bortezomib, lenalidomide, dexamethasone (VRd)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VRd) has demonstrated tolerability and efficacy in prospective phase II studies. This regimen is currently in phase III trials. Although there are no randomized data demonstrating superiority over either VD or Rd, the VRd regimen is commonly being used as initial therapy in the United States. Typically, the dosing schedule used in practice is a modification of that used in clinical trials in order to reduce neurotoxicity and dexamethasone-related toxicity. We typically use bortezomib 1.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once a week, lenalidomide 25 mg days 1 to 14, and dexamethasone 40 mg once a week [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatments are repeated every three weeks as tolerated.",
"   </p>",
"   <p>",
"    The following studies have evaluated this regimen in newly diagnosed MM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      followed by maintenance or transplantation in 66 patients with newly diagnosed MM [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/23\">",
"       23",
"      </a>",
"      ]. All patients achieved at least a partial response with 29 percent achieving a complete response. At a median follow-up of 21 months, estimated 18-month rates of progression-free and overall survival were 75 and 97 percent, respectively.",
"     </li>",
"     <li>",
"      In a phase II trial (EVOLUTION trial), 140 patients with newly diagnosed MM were randomly assigned to receive initial treatment with twice weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      and weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (VRd),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (VCd), or both (VDCR) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/26\">",
"       26",
"      </a>",
"      ]. Following four cycles of therapy, overall response rates were 73, 68, and 80 percent in patients who received VRd, VCd, and VDCR, respectively. Corresponding rates of very good partial response or better were 32, 22, and 33 percent. Approximately 75 percent of patients receiving VRd experienced at least one severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity with the most common being neuropathy (17 percent), thrombocytopenia (12 percent), and neutropenia (10 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2236500\">",
"    <span class=\"h3\">",
"     Bortezomib, thalidomide, dexamethasone (VTD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial results are available from randomized trials comparing the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VTD) with thalidomide and dexamethasone (TD) and bortezomib plus dexamethasone (VD):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy with the combination of low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1,4,8, and 11), low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (100 mg daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg days 1 to 4 in all cycles and days 9 to 12 in cycles 1 and 2) (vtD) was compared with standard dose bortezomib (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1,4,8,and11) plus the same dose of dexamethasone (VD) in a randomized phase III trial of 199 younger adults with newly diagnosed myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/31\">",
"       31",
"      </a>",
"      ]. A significantly higher percentage of patients assigned to vtD obtained a VGPR or better response after four cycles of induction therapy (49 versus 36 percent) and after HCT (74 versus 58 percent). vtD therapy was associated with a significantly higher percentage of patients requiring the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in order to collect an adequate number of stem cells. Peripheral neuropathy was less common in patients assigned to vtD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H3#H3\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Collection of stem cells'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A randomized trial of 474 patients with newly diagnosed myeloma compared the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice weekly),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (200 mg daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (320 mg per 21 day cycle) (VTD) with the same doses of thalidomide plus dexamethasone",
"      <span class=\"nowrap\">",
"       (thal/dex)",
"      </span>",
"      each administered as induction therapy before, and consolidation therapy after double autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. There was no difference in stem cell mobilization between the groups. When compared with",
"      <span class=\"nowrap\">",
"       thal/dex,",
"      </span>",
"      VTD resulted in higher rates of VGPR (89 versus 74 percent) and progression-free survival (PFS) at three years (68 versus 56 percent), but also higher rates of severe peripheral neuropathy (10 versus 2 percent) and skin rash (10 versus 2 percent).",
"     </li>",
"     <li>",
"      In another trial, 386 patients &le;65 years with previously untreated symptomatic myeloma were randomly assigned therapy with VTD, TD, or conventional chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , with planned autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/34\">",
"       34",
"      </a>",
"      ]. A significantly higher percentage of patients assigned to VTD obtained a VGPR or better response after induction therapy (60 versus 29 and 36 percent). There was no observed difference in stem cell collection among the treatment groups. After a median follow-up of 35 months, the estimated median PFS was longer following VTD (56 versus 28 and 36 months). When compared with TD, VTD was associated with higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thromboembolism (12 versus 5 percent), infection (21 versus 16 percent), and peripheral neuropathy (14 versus 5 percent), but lower rates of gastrointestinal distress (8 versus 25 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no significant difference in overall survival with the three-drug combination (VTD) in either trial. A longer follow-up is required to evaluate whether the improved response rate and progression-free survival seen with VTD translates into an improved overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4997456\">",
"    <span class=\"h3\">",
"     Bortezomib, doxorubicin, dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials have investigated the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with newly diagnosed multiple myeloma. Bortezomib, doxorubicin [Adriamycin], plus dexamethasone (PAD) has been compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , doxorubicin [adriamycin], plus dexamethasone (VAD) in a randomized trial. VAD has not been compared with other bortezomib-containing induction regimens. In addition, nonrandomized trials have investigated the combination of bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    plus dexamethasone (VDD).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 827 patients with newly diagnosed, symptomatic myeloma were randomly assigned to receive induction therapy with VAD or PAD, with planned autologous HCT followed by maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (following VAD) or maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (following PAD) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/27\">",
"       27",
"      </a>",
"      ]. PAD resulted in higher rates of VGPR or better (62 versus 36 percent). After a median follow-up of 41 months, patients assigned to PAD had a longer median progression-free survival (35 versus 28 months) and estimated overall survival at five years (61 versus 55 percent). PAD was associated with higher rates of peripheral neuropathy (40 versus 18 percent).",
"     </li>",
"     <li>",
"      A phase II trial evaluated the use of VDD in 40 patients with newly diagnosed multiple myeloma followed by autologous HCT for eligible patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/22\">",
"       22",
"      </a>",
"      ]. The overall response rate was 85 percent with 58 percent achieving a VGPR or better. The most common non-hematologic toxicities included peripheral neuropathy, fatigue, constipation, and hand-foot syndrome. A second small phase II trial demonstrated similar response rates, but less toxicity when VDD was administered at lower doses [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies are consistent with other trials that have demonstrated the superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -containing regimens to VAD. However, there is no major advantage of these",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing regimens as initial therapy compared with other regimens such as Rd, VCd or VRd.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4997000\">",
"    <span class=\"h2\">",
"     Thalidomide with or without dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (TD) is an alternative regimen for patients who are candidates for transplantation if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    are not available. The overall response rate is approximately 65 to 75 percent, with most patients having a successful engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. The principal adverse effects are thromboembolic phenomena (approximately 20 percent), which are decreased with appropriate prophylactic therapy (approximately 8 percent).",
"   </p>",
"   <p>",
"    The following is an overview of some of the studies that have evaluated TD in patients with newly diagnosed multiple myeloma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III ECOG trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by mouth) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg by mouth on days 1 through 4, 9 through 12, and 17 through 20 every month, TD) with dexamethasone alone (dex) as induction therapy in 207 previously untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/39\">",
"       39",
"      </a>",
"      ]. Combination therapy with TD resulted in a superior overall response rate (63 versus 41 percent). Toxicity (deep vein thrombosis, rash, neuropathy, bradycardia) was significantly greater in the TD arm, including a 17 percent incidence of deep vein thrombosis (versus 3 percent in the dex arm).",
"     </li>",
"     <li>",
"      Another multicenter, randomized, double-blind, placebo controlled trial evaluated the use of TD versus placebo plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 470 patients with previously untreated symptomatic multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/41\">",
"       41",
"      </a>",
"      ]. Most patients did not receive DVT prophylaxis. Patients treated with TD had significantly higher rates of overall response (63 versus 46 percent) and longer time to progression of disease (22.6 versus 6.5 months). Severe (grade 3 or 4) side effects were more frequent in patients treated with TD including deep venous thrombosis (12 versus 2 percent), pulmonary embolism (7 versus 2 percent), and peripheral neuropathy (3 versus zero percent).",
"     </li>",
"     <li>",
"      A retrospective matched case-control analysis compared oral TD with infusional VAD before collection of peripheral blood stem cells and autologous transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Results included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In comparison with VAD, TD resulted in a significantly higher overall response rate (76 versus 52 percent) and a more profound reduction in myeloma cell mass, as measured by reduction in immunoglobulin levels.",
"     </li>",
"     <li>",
"      Deep vein thrombosis was more common with TD (15 versus 2 percent), while granulocytopenia was more common with VAD (12 versus zero percent).",
"     </li>",
"     <li>",
"      91 percent of patients from both arms proceeded to, and obtained, successful stem cell mobilization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have tested the addition of other chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    ) to TD, but such approaches increase toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]; additional data from phase III trials are needed to determine if the benefit is significantly better than what can be achieved with oral TD therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4997022\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many dosing regimens have been used, we administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    200 mg daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    40 mg by mouth once per week of a 28-day cycle (",
"    <a class=\"graphic graphic_table graphicRef82300 \" href=\"UTD.htm?41/56/42893\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/13\">",
"     13",
"    </a>",
"    ]. Note that the dexamethasone dosing is lower than what was used in the original studies (40 mg days 1-4, 9-12, 17-20 every 28 days), and is based on recent studies suggesting a higher mortality with high dose dexamethasone compared with low dose dexamethasone given in combination with the thalidomide analogue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of TD mandates routine thromboprophylaxis to prevent deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/16\">",
"     16",
"    </a>",
"    ]. In the United States, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is subject to the STEPS program developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Thalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     VAD chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy with VAD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [adriamycin],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) has been used as initial chemotherapy in previously untreated patients in preparation for autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/8,45\">",
"     8,45",
"    </a>",
"    ]. In a report in which infusional VAD was given as initial therapy to 75 patients, the overall and complete response rates were 84 and 27 percent, respectively, and median survival was 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major limitations to the infusional VAD regimen are that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    have to be administered through a central venous catheter, with the attendant increased risks of sepsis and thromboembolic events.",
"   </p>",
"   <p>",
"    Due to equivalent results seen with oral regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (TD) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus dexamethasone (Rd), and in order to obviate the need for a central line and to prevent neurotoxicity from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , the use of VAD has greatly declined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/47\">",
"     47",
"    </a>",
"    ]. Accordingly, we currently do not use VAD as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H2#H2\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Initial chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the infusional VAD regimen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (0.4 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (9",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    are given each day by continuous infusion for four days, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    40 mg by mouth daily is given on days 1 to 4, 9 to 12, and 17 to 20 of each of the monthly cycles. Dexamethasone is usually given only on days 1 through 4 in even numbered cycles to limit steroid side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Modified VAD regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of regimens based upon VAD have been evaluated. Overall, they result in similar efficacy as TD or Rd, although they have not been directly compared in a randomized prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, these regimens are less desirable since they are associated with significant neurotoxicity.",
"   </p>",
"   <p>",
"    As an example, a prospective multicenter study evaluated the efficacy of bolus VAD in 127 previously untreated patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    (0.4 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (9",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    each dissolved separately in 100 mL of saline, were given IV over 30 minutes once per day for four consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    was given as in infusional VAD. The overall response rate was 61 percent; the most notable toxicities associated with infusional VAD (infection, neurotoxicity) were significantly less common with the bolus VAD regimen.",
"   </p>",
"   <p>",
"    Increased response rates have been observed with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    to VAD plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (DVd) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A phase III randomized trial compared DVd to DVd plus thalidomide 200 mg daily in 232 previously untreated multiple myeloma patients less than 75 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/53\">",
"     53",
"    </a>",
"    ]. In an intention to treat analysis, the addition of thalidomide resulted in significantly higher progression-free (59 versus 45 percent) and overall (77 versus 65 percent) survival at two years. Patients treated with thalidomide had increased constipation, peripheral neuropathy, dizziness, skin rash, and edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING DISEASE RESPONSE TO INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy. The preferred method is the measurement of monoclonal (M) protein in serum or urine. Free light chain (FLC) measurements are reserved for patients with unmeasurable protein in the serum and urine.",
"   </p>",
"   <p>",
"    Among patients without an M protein in serum or urine and normal FLC ratio, further evaluation includes bone marrow immunohistochemistry or immunofluorescence and plasma cell labeling index. Details on how to determine response to therapy are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for monitoring disease response is to modify therapy if needed, adjust doses based on response and toxicity, and to identify transplant candidates with resistant disease. In such patients, early HCT may be preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of response to initial chemotherapy on outcome following HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of response to initial chemotherapy does not appear to predict success after autologous hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. This was shown in a study comparing outcomes in 46 patients with primary refractory myeloma and 101 patients with chemosensitive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/54/18282/abstract/54\">",
"     54",
"    </a>",
"    ]. Response of the M-protein, rate of complete remission, and one-year progression-free survivals following autologous HCT were similar for the two patient groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to initiating treatment, patients with multiple myeloma (MM) should be distinguished from patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) who do not need therapy (",
"      <a class=\"graphic graphic_table graphicRef57627 \" href=\"UTD.htm?41/38/42603\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H4#H4\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Multiple myeloma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with MM are stratified based upon cytogenetic findings at the time of diagnosis into three main risk categories (standard risk, intermediate risk, and high risk) (",
"      <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"       table 5",
"      </a>",
"      ). This risk stratification has considerable prognostic value and also helps guide the selection of initial therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"UTD.htm?24/59/25534\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of initial chemotherapy for patients with MM depends greatly on whether or not the patient is felt to be a candidate for hematopoietic cell transplantation (HCT). The principal characteristics that determine eligibility for HCT are age, performance status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence and severity of certain comorbid conditions. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Randomized trials have demonstrated that chemotherapy followed by autologous HCT results in superior event-free survival and overall survival when compared with treatment with chemotherapy alone. In addition, chemotherapeutic agents that are preferred in patients who are not candidates for HCT (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ) can impair the future collection of peripheral stem cells necessary for HCT. As such, initial therapy varies greatly depending upon whether the patient is a candidate for HCT (",
"      <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"       \"Determination of initial therapy in patients with multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are candidates for autologous HCT, induction chemotherapy is administered for approximately four months prior to stem cell collection in order to reduce the number of tumor cells in the bone marrow and peripheral blood, lessen symptoms, and mitigate end-organ damage. During this time, specific arrangements for the subsequent HCT can be made to ease the transition of therapy. Stem cell collection is followed by either early (preferred) or delayed HCT. Specific issues related to HCT are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with MM who are potential candidates for autologous HCT, we recommend avoiding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      -containing regimens as induction chemotherapy. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For standard risk patients who are candidates for HCT, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"       table 1",
"      </a>",
"      ) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus dexamethasone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). With the combination lenalidomide plus dexamethasone, we recommend low dose dexamethasone rather than standard dose dexamethasone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Lenalidomide may decrease the chances of a successful collection of peripheral blood stem cells in some patients, when stem cell mobilization is attempted using growth factor alone. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lenalidomide with dexamethasone (Rd)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Among the same patient group, an acceptable alternative is a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimen such as bortezomib plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and dexamethasone (VCd). If a bortezomib based regimen is used, we prefer administering bortezomib once a week to minimize the risk of neuropathy. (See",
"      <a class=\"local\" href=\"#H4997358\">",
"       'Bortezomib, cyclophosphamide, dexamethasone (VCd)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with intermediate risk MM, we recommend the use of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Of these, we usually administer bortezomib plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VCd) (",
"      <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"       table 2",
"      </a>",
"      ) followed by HCT. (See",
"      <a class=\"local\" href=\"#H4997358\">",
"       'Bortezomib, cyclophosphamide, dexamethasone (VCd)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/1\">",
"      Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/2\">",
"      Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117:6063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/3\">",
"      Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/4\">",
"      Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/5\">",
"      Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/6\">",
"      Goldschmidt H, Hegenbart U, Wallmeier M, et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/7\">",
"      Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (&gt;/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/8\">",
"      UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/9\">",
"      Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/10\">",
"      Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010; 115:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/11\">",
"      Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116:5838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/12\">",
"      Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/13\">",
"      Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/14\">",
"      Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008; 22:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/15\">",
"      Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na&iuml;ve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/16\">",
"      Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/17\">",
"      Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/18\">",
"      Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/19\">",
"      Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008; 141:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/20\">",
"      Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/21\">",
"      Jagannath S, Durie BG, Wolf JL, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009; 146:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/22\">",
"      Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009; 27:5015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/23\">",
"      Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/24\">",
"      van Rhee F, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/25\">",
"      Sher T, Ailawadhi S, Miller KC, et al. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol 2011; 154:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/26\">",
"      Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119:4375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/27\">",
"      Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/28\">",
"      Rosi&ntilde;ol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25:4452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/29\">",
"      Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28:4621.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/31\">",
"      Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118:5752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/32\">",
"      Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/33\">",
"      Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/34\">",
"      Rosi&ntilde;ol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/35\">",
"      Berenson JR, Yellin O, Chen CS, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol 2011; 155:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/36\">",
"      Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/37\">",
"      Dingli D, Rajkumar SV, Nowakowski GS, et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 2005; 90:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/38\">",
"      Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/39\">",
"      Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/40\">",
"      Hussein MA, Bolejack V, Zonder JA, et al. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol 2009; 27:3510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/41\">",
"      Rajkumar SV, Rosi&ntilde;ol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/42\">",
"      Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/43\">",
"      Cavo M, Di Raimondo F, Zamagni E, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009; 27:5001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/44\">",
"      Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012; 97:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/45\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/46\">",
"      Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/47\">",
"      Vogl DT, Liu SV, Chong EA, et al. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Am J Hematol 2007; 82:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/48\">",
"      Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy (editorial). Blood 2005; 106:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/49\">",
"      Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/50\">",
"      Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/51\">",
"      Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 2006; 106:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/52\">",
"      Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/53\">",
"      Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007; 18:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/54\">",
"      Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/54/18282/abstract/55\">",
"      Arzoumanian V, Hoering A, Sawyer J, et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008; 22:850.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6647 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18282=[""].join("\n");
var outline_f17_54_18282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDUCTION CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lenalidomide with dexamethasone (Rd)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bortezomib regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2236472\">",
"      - Bortezomib plus dexamethasone (VD)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4997358\">",
"      - Bortezomib, cyclophosphamide, dexamethasone (VCd)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2236493\">",
"      - Bortezomib, lenalidomide, dexamethasone (VRd)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2236500\">",
"      - Bortezomib, thalidomide, dexamethasone (VTD)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4997456\">",
"      - Bortezomib, doxorubicin, dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4997000\">",
"      Thalidomide with or without dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4997022\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VAD chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Modified VAD regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING DISEASE RESPONSE TO INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of response to initial chemotherapy on outcome following HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6647\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6647|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/52/12111\" title=\"algorithm 1\">",
"      Therapy approach MM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/59/25534\" title=\"algorithm 2\">",
"      Therapy approach MM II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6647|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/61/26589\" title=\"table 1\">",
"      Rd for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/43/33470\" title=\"table 2\">",
"      VCd CyBorD for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/56/42893\" title=\"table 3\">",
"      Td for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42603\" title=\"table 4\">",
"      Diagnostic criteria for myeloma MGUS and SMM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25099\" title=\"table 5\">",
"      Risk stratification of myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=related_link\">",
"      Initial chemotherapy for patients with high risk multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_54_18283="Risk factors complications";
var content_f17_54_18283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for the development of biliary complications after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Roux-en-Y anastomosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of T-tubes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improper surgical technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inappropriate suture material or excessive tension at the anastomosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive use of electrocauterization for control of bile duct bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mismatch in size between donor and recipient bile ducts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO mismatched grafts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute hepatic artery thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic artery stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemia/reperfusion injury (ischemic-type biliary lesions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non heart-beating donors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary sclerosing cholangitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres C&aacute;rdenas, MD, MMSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18283=[""].join("\n");
var outline_f17_54_18283=null;
var title_f17_54_18284="Rx pneumonia pregnancy";
var content_f17_54_18284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of treatment of pregnant women with pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. The indications for chest x-ray are the same in pregnant as in nonpregnant patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Provide supplemental O2 to maintain oxygen saturation &ge;95 percent or to maintain maternal pO2 &gt;70 mmHg. Maintain frequent or continuous evaluations of oxygen saturation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Obtain blood gas especially if there is concern for CO2 retention and remember that the normal PCO2 in pregnancy is 25 to 33 mmHg. Thus, a pCO2 of 35 mmHg already represents CO2 retention and possible impending respiratory failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Treat fever with acetaminophen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Consult the obstetricis service for fetal well-being assessment (such as fetal heart rate monitoring, obstetric ultrasound). This may require the presence of obstetric nurses who are comfortable with fetal heart rate monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Monitor fluid status carefully as these patients are prone to the development of pulmonary edema.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Obtain blood cultures and sputum for gram stain and culture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. The choice of antibiotics for treatment is similar to those used in nonpregnant patients but because of an increase in renal clearance, higher and more frequent doses may be indicated. However, the use of tetracyclines, clarithromycin, and the fluoroquinolones should be avoided.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. If indicated, obtain serology for mycoplasma, and urine for legionella antigen and legionella culture of respiratory specimen. The FilmArray&reg; molecular test is the best test to detect M. pneumoniae, C. pneumoniae, Legionella and B. pertussis. Results are available within 60 minutes, sensitivity and specificity are &gt;95 percent. However, it is not universally available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Try to anticipate intubation well in advance so appropriate equipment and experienced personnel are readily available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Try to position the patient so that the gravid uterus does not obstruct venous return (ie, on left side or with right hip elevated, if necessary).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Bronchoscopy can be performed safely in pregnant women and should not be withheld if the information obtained will be important for the management of the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Ill pregnant woman confined to bed are likely to benefit from prophylaxis for venous thromboembolic disease.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18284=[""].join("\n");
var outline_f17_54_18284=null;
var title_f17_54_18285="University of Washington Burn Center Pain Medication Guidelines";
var content_f17_54_18285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    University of Washington Burn Center Pain Medication Guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Critical care treatment (without oral intake)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Critical care treatment (with oral intake)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-critical care treatment (large open areas)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-critical care treatment (small open areas/predischarge)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Background pain",
"        </strong>",
"       </td>",
"       <td>",
"        Continuous morphine sulfate (IV) drip or scheduled doses or PCA",
"       </td>",
"       <td>",
"        Scheduled methadone or extended-release morphine or PCA",
"       </td>",
"       <td>",
"        Scheduled methadone or extended-release morphine or PCA",
"       </td>",
"       <td>",
"        Scheduled NSAIDs/acetaminophen, oxycodone or none",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Procedural pain",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         General or regional anesthesia or deep sedation for severe pain",
"        </p>",
"        <p>",
"         Morphine sulfate (IV), fentanyl (IV), ketamine and dexmedetomidine (IV)",
"        </p>",
"       </td>",
"       <td>",
"        Oxycodone, fentanyl IV, or oral transmucosal fentanyl or ketamine",
"       </td>",
"       <td>",
"        Oxycodone, fentanyl (IV), nitrous oxide (IH), or oral transmucosal fentanyl or ketamine or propofol",
"       </td>",
"       <td>",
"        Oxycodone or ketamine or propofol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Breakthrough pain",
"        </strong>",
"       </td>",
"       <td>",
"        Morphine sulfate (IV) or fentanyl (IV)",
"       </td>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        NSAIDs/acetaminophen or oxycodone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Postoperative pain",
"        </strong>",
"       </td>",
"       <td>",
"        Continuous morphine sulfate (IV) drip or scheduled doses or PCA",
"       </td>",
"       <td>",
"        Scheduled methadone or extended-release morphine or PCA",
"       </td>",
"       <td>",
"        Scheduled methadone or extended-release morphine or PCA",
"       </td>",
"       <td>",
"        Scheduled NSAIDs/acetaminophen, oxycodone or none",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Chronic pain",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Gabapentin or other nonopiods or antidepressants",
"       </td>",
"       <td>",
"        Gabapentin or anxiolysis or NSAIDS or antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Anxiolysis medications for background and/or procedure management",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Background anxiolysis",
"        </strong>",
"       </td>",
"       <td>",
"        Scheduled lorazepam (IV) or continuous lorazepam (IV) drip",
"       </td>",
"       <td>",
"        Scheduled lorazepam",
"       </td>",
"       <td>",
"        None or scheduled lorazepam",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Procedural anxiolysis",
"        </strong>",
"       </td>",
"       <td>",
"        Lorazepam or midazolam (IV)",
"       </td>",
"       <td>",
"        Lorazepam",
"       </td>",
"       <td>",
"        None or lorazepam",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Post-hospitalization pain control",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Discharge or transfer pain medications",
"        </strong>",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        For transfer to non-critical care treatment: wean drips; establish PO pain medication early; anticipate dose tapering as needs decrease",
"       </td>",
"       <td>",
"        Oxycodone for procedural pain; methadone taper or extended-release morphine; taper if applicable",
"       </td>",
"       <td>",
"        Oxycodone or NSAIDs for procedural pain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative pain and sedation management guideline for adult (nonpediatric, nongeriatric) burn patients from the University of Washington Burn Center. General medication recommendations are provided for specific pain and anxiolysis needs encountered in various intensive care units and ward-care settings. Medication options are intentionally limited (for simplicity) and do not include specific dose recommendations (to allow for individual patient variability). Complex or refractory cases are managed through special consultation with the burn care team and/or pain specialists.",
"    <div class=\"footnotes\">",
"     PCA: patient-controlled analgesia; IV: intravenously; NSAIDs: nonsteroidal antiinflammatory drugs; IH: inhalation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18285=[""].join("\n");
var outline_f17_54_18285=null;
var title_f17_54_18286="Mutations in TSH cascade";
var content_f17_54_18286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TSH receptor and G",
"    <sub>",
"     s",
"    </sub>",
"    -alpha are oncogenes in toxic thyroid nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 279px; background-image: url(data:image/gif;base64,R0lGODlhsQEXAeYAAP///wAzmaekqf+ZMwAAAICAgMDAwEBAQFNSVAAZTPDw8D9mshAQEDAwMH+ZzKCgoNDQ0H9MGb/M5eDg4CAgIAAMJmBgYFBQUHBwcLCwsAAmcgADCZCQkO/y+A8/nx9MpZ+y2AAvj19/vwATOa+/3y9ZrN/l8s/Y6wAGE2+MxQAjaQAshQAPLwApfE9yuI+l0gAfXwAWQgAJHAAcVl85E317fi8cCR8TBikpKu+PL59fH9+FLK9pI898KYeFib9yJk8vDwoKCj8mDJyZno9WHD49Px8eHw8JA5KPk3JwdG9CFhQUFTQzNElHSWhmaV1cXwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACxARcBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6ekGBe3u7/Dx8vP09fEG6vn6sQU4CP8AAwocSLCgwYMBcRTYx7AhqgIIBEicSLGixYsYM2qkiGChw48gPUHcSLKkyYwdQ6pcaWnkyZcwNaZkSbMmI5cxc+qcabOnT0E4dQo9yfOnUZZBhyqV6fGo05BJl0qtWPSp1X1Rp2qterUruqxapXL1SnYc2LBKx5Zd6+0sWqFq/9nKzeb2bc64c/NSq2sXJl69gJ/x7Uu0aeDD0gYTLvkXsWNjihdvbPy4crDIklEatsy5GObMFyl3Ho3rM2iqm0mr5mX69ETRq2O/au1aAGzZuFXRdn07t+9Su0/3/k0cVHDQw4sr36TYR43nz30IGOLkn3QBzyUiqYFEgPPn3V8mX06+ZcSSOAioV4/DR5AgOJYQqCFAvUQEBCKmX99EfOryAH7SXA1FEFBEDT6kl4RESUhnn235CZAedw+aNF4qBmSYoT3uaJhhgCthht95BQbBxBPhqfdPevrN5wMBS/gnywQGPNDOAQc0sJ4MFfRYQQwJBCnkkEHG4GMFMqzXAP+O7TxgwAQgpiNihNMVqF4QDq6nooTrYSmjKjQWgMEBFBCwQQUsBKmCBhoE4OabcMYp55xusqlCkCxUsAEBFByAQQFPRhnOlOcNIVENLNZHwH0RpteEetdZ+N8nBnAwppkVjJCABi3Q6emnoH7aggYJGLmnnxzgI6g2hEqEQxFJ1GDEfIoy2mIN+C1hqKShTPAABjqikKYGK4Rq7LHIyrkCqSygQEADGDwA5ap7nWchlU/MSoARC9YK4a0CzFpEYZ1AwMEFDGwwbAjJtuvuuyEwuwEDF3AAAbXQHJfZhYQo8IAFFKg7Q6fvFmzwuy3MwMIGFFjwgAL4LqOvZPyaq2P/BQMfrPHGCM9QwbP2RnzMxIslBwEGAY+gArsct+wysiGoMALDGNwrsjAkE3bbyRSgEEObLwct9LEaxIACBTXf/EvOfVGmAAcNbDAC0ENXbfWnGszcAAcQK60L03b9lcEFBLCgwtVop+2pCiwQcEEGXpdmbW1fGvJ0zwkUq/befL+5QgJHcx03LWC/xdUEFjBQwdl9N+64ChUwYMG0g882N928DmIA2SPo7fjnja8w8wWqVs5K4WjNZMABGyTAMuiwNx5CAhscULrpD12OOUkdrd7667EH3/fstd+OOymoh4VAuq4L7/znxB9A+fGiJC/VEEX8/vz20NM+OfXV6757/2hBdM79+Z+LzsCk4GNivVA1LFEB1ejX37cGFVBgfPvuiz/+dEzYwAzsR8DPzWADF+ga//r3P4skIQgsAF4BJ6i2ELCAAXBb4CXed5IhBJBxFAwh31SAQAU2AgI24pAKV7jCB9iMLRwsyQMjKMIa8s2CGGTEBFB2AyBE4IdADKIQh0jEIhrRiEC4AdKm15UYbqQJGwChDaeYNhJiQBEFIAANejCALnrxi2AMoxjHSMYyerEHNCAA+4ziRIwgwQgy8BwV53i1FcigAUwEgAIaYIMdmPGPgAzkH3dggwaY8ClttEgNghADOjpSbTFgwO32SANBWvKSmKSBIZvoP8k4Yf8DMHikKNEGgw08YBANqCQmV8nKMmqSk5jLHsFGScuhtWADFgBAAWzQyl768os2WGNNEglAGUiwlshsWQhkQDY//vKZrNwBAfLok0QOwQgVOGYyt6mxEFTgBjmApjgzeUVE+gMh6EznP4wwAm66M2gjsEE4x0nPP/aAAlZhBwv3GQ8MEKCd7wxoy+I5z3oaVIw3eKFy9ghQgTpUYwQ9qES/CIRTLoehD80oROU50YlGQJiqwahGR1qwiHbUoB9djgVkQNKWvksGqjwpPVNaHAwY06U4hZkMlCDTmYK0Mw/YwCxz6rwPpMABKSgBnYyKVKWWYAFQhWoJPBBVpR7sljr/6Kk4aeobCDCAfkQNnggEIQETAGABchorAMp6VgkUQgILIMQJPHAwDRyBi1r9JVdxs8cEBI1NbBrSmtg01LDC6QMA6IBVXWDVNyFWsW5i7FNBAAAQLOCpaw0ACQCQAo0lgKOszMEPfgDGHvyQB/Xcq2wsUIFjxYtNMxDSkbTEox4BKUhHctaOfJQmIcEAsMS6qja5lwIAvOBTxT2unBwAAAe4Ka4SCABznauxCsQUk0pQD2q7mMb1RMCnvsnABl63rCL5aE/q8ZGm1ATY4YYKuDAYUp7OqyUUHGm9m5Ljm/TUPLSJwAEATkFUoUpXT003AINYAHMFoeDmIpjBbjpw/wDiagIHdAAAH9hYCDawXUzeQD2q1AEB+jgAHmR1nKoNKQOANIKPESBTQQKsfp03KsDGNgEtTq+mgovef874ZQs+hAlc4CkXZHYBJzjrB6LqASNHF8lnjbCDJ5xYCZAArRxTwREKKkgeEIAIRyBAOIFAgA6n9qeAmQAHLHAAHee3luXNsZbWwwKwuiyuhjCBCEKVZMsmGctw6jOUsSxh6AqNBdcNZBp3kMasCoEApD1oihGjgAwAjF7tGG9GVTDn9VQglBz7gAte4NZC6PlYHgDBhTtAggzHKdWrbrWUqWvooG040oHMgXqE8GFepvG7XXTmVtFMFnboqAGAQuUAM/86g04TwL6LM9gCUkACs0rAAS7wgFkT29lkzoCXgiSCFn/44R5Ic9w2APawEfMAdDUsA4d8AApGeqcEDPZgHxDBC5J8AhCIoLFuUrUDCrxNFJwYkDYQcxezy9MfJHzEuIbmpMuigAJQYGvUFAQFQG1YY1HVASToQAeuvQCCy+kDJt8mDG6Q11VOvCuIo9f+CvGA1nb8UyUQAQj4/QIRuLrjFTh4ywP58qdsTnIZLwQFpHjzAHxcAiIngQMA3XQ3qYDlQxdk0Y3ygAZQoACHTIS8q16CFIDA2i9wwc+fB2A45S14Bs+6GX9AhAgI4QDxyIABwr6SCRSAAQ2w6CMOwHH/nIraAW41AQkEXMC2uykBFfhx32AgBLmXlgg0SLgNaGB3vL9jTDp6lp8eFhIDWIAAFpj5Iiag6ZZOu9prxXbKCej4AARJeBsW9tB5AIQjHAEIRIj4yxVggAwUoAGSU2g+MoD8AiR9ERhoqEPzTWoA9Dupc6w9CgoPuxHwNOtejgBew7j1QUAgcYHn+zgUgC7BU4IChd2mgkM+8qnPfoqOh8G8aYx1g+5A92CUA2ZGfsSmR12XfOeQAfSifo8AAfuXTDm3b9bnbwA3Si9AXSzAfbGDAuOHYuDUSuV3COcHeBkUDuyXQ5iAAY00Sk8XdVMXUHAVACFAAO7lODHwfeLE/wMfJnSYFIKI4C998nzWoIAJpAkNYGc1VHY7t1Y9t3YBZQJKBQMswD0aAG7P1AOPNmK+VFGXUHFqxIDTMAFkUoKYoAAEMEVNhngAoHiM11IA4CYssGzbo3C+lAPdpR4Rt0oJlQliSAFkWA1eCHackAE2N0GvZ23Y5oQkVQIm4CZCdT4VMICYBGZaAgS+dE+DGIRDqImdUAB+VT+iVn0mAALYd3MLEF23hD4JoG6rJG5zBoDk1AmBCIbJgAEo6AkHwHTBM38mUH/ZVnVv4gDHpTDoowKV10t3SACsuErSJISU0If3ogDKhwwT0AB4FAoMIHl8Q338RoHAOCeLFwAjIP+H27MCR+BLIqYeH9hLwSQKD4BBF8cMXlVOoXCGjtOCrGZ/3/gpkCUDSCg8BNBLIqYDjeZLryQKClAm6uGMvqAADOB+lMJSe5NzS3gCTbiPxlICHeAm9og+MpCHXUYAJ8aDmbRJoQABCqkeHKAMF3ABpGAAhWgwTFWKb5KGibd4VIeRxkJtAaABEok+FQCSgXQDRPBMhGSSJ8kAWtIAyaCAtJgJDzCFB6NWbIVWH3B2TKh2Olkw4TgD0sc9LECSgKQD/ddKaKRGplCNWsKQuuCQf2gcn1gwj7VYVtWGW3kwkHV79ZMAQnBERnQDfemXR5RES4QKe7QeK2kMLWkKnnj/MMl1l0OjkY8Xl+eTAJ63T2TCT/HgQqygAKf3LMbwjk+pCY1pMAeWYJDJMTxpe5TJPQlQgBoHkcLwmWxpCwZAAG8ZCqVZME42YX+WmhtzAnvGmvbzmpHwAPiEDA9AAImJM/QIHK3pLoL2m8ApbY04mcUJmxYAm7nwAAdADBNQm5mwmwUDa4klaxM0kxVYMBKgXHJCakEjdW+il6oIm7azDNOIDlHZUlRpVjn5Lpk1J271Mh/QAQRHn+fDArK5CNNEPTBJUnMZWesJKgtAAhIgAd2WWf91iiBAV27lAiRAAkp1lRf6Avf3KSAAAm4Xnc9TAaqHCBNAAOBjAD+ZUY9p/5ogoIZ7llluBQIvAAAkEACJl2SNeIoOQFkqiiwe0AFrh6DcIwMvegirIxdqVgAhAwEeYgD34iH1aDUWmohs52CoOSd4NmVu4gHUlmTOxaNvGABJJqRt+qYBoHNuFV3IAnJx4qRzGAkFkEtrsZwEQCYEsDpz9p1awgD5iQnZWDWpNgj192+w05uDRidUBVVrdwIdkALFtabRNaBw+qmf+qMvUGvHYgI5qafOswIMEAlrthYxiqiCkAEQgKWnl3r3oh4AwAFu8wm5eDU/eggnmjbTGWX/JQLB+iZruAA/yqlwOm1ACqoD+qFjZafGIgInICeoelhHhX1PNWBKNWAto/8C3wkJBsCUyEB8pYOumrN3AIClGTKanKCrzzkIWdQUuHqb49qJLPoyakUISfo55slqV1lhVxYqVCmmnbqGa+WhbTqgGrlWAWosp5an++om/dlWb/VgggBZnsWdMooM/oSbgnCbBHAvgIoPbbYeC6qbaLkeqlKvg6Aex0cAK3sJhJg2LnBhg0Bdz/Oj/XasoeKpQoN4c5KtARChASBZC4Ckl/VgAVBcQSoCF0oCRJa0FmpZE2ahJhonFZCbi9AAUXoLO3QAb6Nx6uGnJJtLoYeygwoBBLCqp5ABgQoA5TqoQIGWgqAeOFKzXdiRV/Owa2UCEys8UDVWPPsuQvsyS/r/n8RJJzcaJxLmtIZGAhdoVvkGpCCHbUD6o0EKJwQAr4RgAc3ZCw65PmwGAHLLAUoJMbdZJq1rt22GD7iKCjqSejrysngLALMrCg2gi0PjAUmWYadYYUCbNr8qAYroPC/QudhasacJYdJlpoLgAEm2Zx+AeP5ZXCfgAHu2WQBmVnCiAebKqn7qC7pqUVByeohDs3SrRgxAL7ELAG1mAWRTvqbgmUpJL9MCs3n7saKggnvjAYd7ih0wcDqJWMnbuHMiqdQZuWQlAdbbAcJJWWilhsblVgBWewEQA/PqCOUKDFmUrnpbJkx5m2KCm/HbZksiiN3ggLFDwAb8jZTrKUbr/6aVNanRy7OCACdxdWVuNW2jOlaLB6QL4AL/GgAokKiM4L+94LZg2266up0WV7ImTHzyC7t2Gw7wt4tQF8OmaKA0vIKUqmrn6WoO3KZvQlkSfFYusG0kQFcO4MZv0gLJOQlgCwzMJ7M60jX+hAEmPAgpnMXgEH1FpWogkMAtdW1YE5POMwId/Aii2z6sV4N9c5WVhcgZJQLX6Skt8IDOs2HiSXN1TD2Exz2WfMg4pZFV+yl+KzwwkK/vx7dKM3bnc8qYzE0aOZygggLxBzsoIMuMgJz8s3SgaGFY+1DA656gMj/PowKjXAkUAMwiU3MEJMAjx7jIBLxHDCpA0qLSrP9DoIsvG1dA1hyD7mShyVIqzgMDz6xBlUDL5Gxh5ixKTRZwc5Us+OM8v+zORkiO1azJECxKzPVfJlC8cdLJwjMD48vPl2AArRdCmjy4aKizADChodLKjrNhYcvQkCyVNRTRulxDQVZZ78LLscMC9svRluCQvjtBIF1DS1oIh3sszAw6KsAA4VwI6jqyWRqeGhLKtADU3yBelGw/UqtnBh08I90Bq5ws3Qw9G+C1jhCyGdRp7aAlKf0Lf/IRrOVIMJzUAEvRb1wwUgg6FZDVkaCQaFu3qeJ3X1gmSqwL9+kQffVIX10/C8bUB7MCG/A5CYCUk5C6qwvIWQyz8SsMDCD/1N/gVf9YQ3e9PTE91hrjj42jAbBqCep7eoJ32FnkJ3wyDGaoEkHVy1O0tAV8y3wTx019MDEgxmpzS9+cCGYYqCRM2LjbJ98jDFOqEjZV1CFky8LjxRvjkzckA4/MqqjXDnAtCJydu8NwLiyxUsgE3Mi0AdoYNDKA1pKwx4LQx8xd2M6NM9xJDiJVS9Q9ShmoNiMA2PtwAFLNEOVt3oaM2hQEA4w8NOud01oc1/DdAF9JS+WMzSK0Yde9MfkdEkzMEvGdzfIs4BSkKVZz4CBhAO28EgvO4Nc8RxrgyS8j4SCRAbBcE3uUTe8kwCYwzzWEAo1dMN7E3g7RDkbBfjf1/zmjQiQ2LiTB9S4v7SnquVTbalXg+ibdWnIGg2Mvs0xFuBIXENsOYQGPiDY1biTOYl+3deNCImcwNiQZAyoRnbwX+59frrGJNZylJgghnSx87dvGckva7RB37BRBpYEaowEzIOXP9iObQtqgUl5EsjDqQiS6aKwnl1h0GSdIy1hO+wG/+cMlkFgG82kcU0pMng4JbhQGsGIaswIwYCTPtmN67jIJMyQxQAAtHSePOyen7iY7PKfP+sNOS9YooOaeEkkbvQ9eBXMNEEfJEi+QtwFnsimybjUrYyzPe1ZB1mBrCmGrbmg9ulnb3C4VULGhYkfXaBO73RUYEEWhAgMj4P8sPwIDBU5ADKxkTDbuaLXqY6WibnUC1wbWc6IB1v0uVvQTYlIWCkhDc6J/KDADK25Dw/qf//5gCyACIpdhrs4xI/DfoIJD7x0SkUxxF6DtcKLvcv5IAYuecHLxGUYIIuomB78xfN3vcEJCSf4Tc70W984uKoAC21edLwN5xsLwT9GgcsF+ZwJKLm9rLf8pB1TyMV7p9v6+NZ3zLqPpkoc/+nMV194VsyoIJwg3f2c+RN8yCVCjbqI+4/0RreoVE8AAFFBpCzgIiKM9U78xMhCXxJPb2J71dB16FHCLhCCGZF/2BdMCBNAC0aPYIXHyT3GY6/HevtNfdO8ugFM8cnH/2Vbxmevx9YsQ+MFO98QjOSPLFkD/E4qvJPw9shEv9YPvKaKDQFqKwnBbbAt9FICqHhgXCTEXbZ0fJ5CDdINANurR8D7RblYBqKlfCXeDAm83+H8TOAokhlrikmQB404BAQfAAXp/CGNTNqW+lWzjNm+pllqi33s/6Y7xNFEzNamZNRuwNQyoACmrHtgfEm+uHDzjMyLvUkVzNEnTCIpP/F1R+cTBM1Iz7EQVMzODNJkPCACCgwUEhgqDiYqLjI2Oj5CRkpOUkxAUlZmam5ydnp+VEBwNBBUzLQGpqqusra6vsLGys7EtMxUEDRwQng+GD6DBwsPEABkHxcnKy8yc/woPFhQbLKe01tfY2ay2LBsUFg+IwRAMyM3n6MEFBent7u/jHBcM0wkaIdr5+rQhGgndDC7sUnZpAryDCBMJTMiwoUMAEx5gIIWChb0V+zJmW+GPBYpcGB4YPKdg5MOTyg4YQMkS0gQOBQYCMEBz5aAJNU22nMkBwwECGyqMsIdKo9EW/kZU2EDgAAYONh3WjLqz6iMC4qxW9dWUAoGVhgwxAAagUFgLWhPhLODTa1CLCVRo0GC01VwVCf4tJUDBaQEDOlGGJcCAV9q0Dx5kYHB45wTChjPwMgSR1MpCBRR4NdxYEc4H6w4cIGVIRoXTFWLkXc16tVLUMsI2EL3uAf/gzgAocyBwAXdVs4QPcPaNcDeGRZQB+OqNGcBPqsQfTTUAc53169anR29E2UDT7SiBEwaPsHlYsAQEeUdWyClf8vDdGSpAimz8hBkGs7vfLj8yA5bllp5yBKBVSF8WBMbfgsIYIpp9DL7jXVhZRcgMKRYA+JWABjzAAAMGNWfhiMEkR+I7EJx1IjMKWMAAYRcYNNgFhom44o2VmIgjOmEpuOOPQAYp5CAODmnkkUiO+FySTDbpZGcHYPLklFRWmRA4Vmap5ZbFcMDll2CGKeaYZJZp5plopqnmmmy26eabcMYp55x01mnnnXjmqeeefPbp55+ABirooGFOJYxTkSD/OggEB0BI6KNNDlaYJD85UoCjjHx301+Qdhppersx9wAE7CjgkwW8GOAVpwZc4BQil85UQAYWHJCBIt+RmsEEnIKWwQU0zuTqAV4CAEGtFwCjQAEHXHArAByIhoGPnlZ7UnffEUZZAwzQB6KHTSnGGwa85cZecIbo1JQCDDSggHfs/EQBKZgUYAGzBIiUi729cUsfAccSgAF90FlrsEPz1ZdbA4KkeFx+XlYKwAUErOOVuWVtSC5VTR0wKbzODUgKAArIQ0oBKVLwlAIpHmBvxRRfwOnBND/kYKOCaAoyyBL/dB3GhVy2IZF8bcjzgJVyy8Fu7BzzYgPrZdciac/W/2y1MhlUiOuARJoDAAMUtApwyJKFagCtQG8YdCK5pPxuxSELUilfBpD7lwUZGPDh12NRBw1U5BZ79eDCFACiIzpi3DC9ZC1GgJcFeFXud2uv3XXGFxwtd3pc+TwBaQ3wAgHFfGVgOGHHEa66JwpcEPrqsKP5+QFax277l3qnfvvuX3IwFu/Aa9kiBcMFb3yTn7t7/PJNkoOWVeswL/0yvmDKUvTTZy+Mi8XvhL324G+iQAPKH/Z9+OhL4jxu56fvPiMeCt5Y++/XDwAGDBScFv32o6/AaNTSCv/6p71LWKB289sPAdHnIQVGZ4ALXJ7hqrYdCEYQeK17HXwseMHbQf+gARdAIHE42EHYLcaBG0RhCXfnO+uBh4QrtNrwupfCGO5udiIkDwxtaK3ckWiHPOzUblx4HyAGkVDcW5ERjwio8ZXvREtkYp/Wh6MoSlFP1fuRFa94pyTiSHJi4eKj/teAAEbIAjMS46AMmEMLccUQ8lNjn+InpMeEhYZypFPWBIE//eGINFLKI55aRkY84ohcBRIknjQjlhAiKT/5UmQXB0PEH6VLknV64x2TNBpM0mkCLxpMgpLEFk/OiTSEyUzzKGjKNiGSApVspSn940dZcgkC0+EMTdq4iHdNpySg4YAZNaGoTBQzEtOy5Zl+MhhzcMWPBVDQhAZjAGYShpf/OfIaJCwXK2XaCZdozBAvQGkIPw4tEb4spwEUkLXxnVNWrQqWAVBmG2O4SnDMQiMyQCMIfs6kVnj7CZa6GS1n9XNWwDKkN8NkI9EsKVO11BGvyqGI9hiOMYV40azGJbD78aY9cYubdxrArAt4pQHH+Q65MECxW8mLXgtNk4h8N4GHEmIwmtpaIhhVjgqtbWOFeBbFEMGtr0npOz1LD8VGwquhfaddJCuXxEYW0zOJyJrlVAtNHmcAGiYuYw6s3Fcsl1TFIRVp6ZGYICyXLXOcdXMLesmlEMgoYBxzp42qKyP0ugifSFJEuNQQBxD4Tp0KQmWng1AhOLAYjA6Nafnp/81PMuALZMQMf6Aq0DzXUTGwWJYApntcSNUKH01qcxAgy6ki4MUr/bUWfioUo40250fhII5rpOtWRYtGvIxFBbOOvERTcuUV1w0ocoTZVXEx1jrUwTWk8HlM/oxVqpLeKrWnbVGzKtbaZQGDV7vilKloo5z9/IpY6plVrVhZVUpYjk7GUYS/SIFLuKkWAKTAABr/AjcKMGaIIPMvWzBRqciuNGPluGR7M/HeOc22ZS/jLztUmyK0wAtkQZ3H29jxoXsZpFJDxa9jV7KxBVursjeJ2jq2OmFt7qyzcHtMOGcCt9F5BUSVKqtYa2niQHnFZa7im204YBv7apNdYbMbyFPwm1We2eYnjMrsRpmjtsL2mFATIB0FvDQ6Q1Agb0ZWBLh8tmRfSAlkWrbrgIALqyrz+MpwjrOc50znOtv5znjOs573zOc++/nPgA60oAdNaDIFAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TSHR: TSH receptor; G",
"     <sub>",
"      s",
"     </sub>",
"     -alpha: the alpha subunit of the guanyl nucleotide stimulatory protein; AC: adenyl cyclase; GTP: guanosine triphosphate; GDP: guanosine diphosphate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18286=[""].join("\n");
var outline_f17_54_18286=null;
var title_f17_54_18287="Fibula fracture above lateral malleolus Mortise view";
var content_f17_54_18287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibula fracture above lateral malleolus: Mortise view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fibula fracture (white arrow) above the&nbsp;joint line&nbsp;is seen on this Mortise view of the ankle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_54_18287=[""].join("\n");
var outline_f17_54_18287=null;
